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Of the Parens Patriae Commitment Power and
Drug Treatment of Schizophrenia: Do the
Benefits to the Patient Justify
Involuntary Treatment?
by Eugene Z. DuBose, Jr.*
Last term, in O'Connor v. Donaldson,' the Supreme Court
decided its first case concerning the rights of the mentally ill
who are involuntarily committed to state mental hospitals. For
those who expected a sweeping statement of rights, the Court's
holding must have seemed exceedingly narrow: it stated only
that the state could not constitutionally confine, against his will,
one who, though perhaps mentally ill, was dangerous neither to
himself nor to others and received no treatment in the hospital.
The Court explicitly declined to address an important question
hovering near, but not presented by, the case: "whether the
state may compulsorily confine a non-dangerous, mentally ill
person for the purpose of treatment." 2
The concern of this Article is to suggest a legal framework
for deciding that question and, by applying that analysis to a
specific treatment for a certain mental illness-drug treatment
of schizophrenia-to demonstrate the difficulty of establishing
a case that any particular form of psychiatric treatment can
validly serve as a justification, under what is usually termed the
* Assistant Professor of Law, Northwestern University School of
Law. There are a number of people to whom I must give credit for
much of what is of value in this Article: my colleagues Mayer Freed
and John P. Heinz, who were generous with their time and energy in
criticizing an earlier draft of this Article; Dr. Norris Hansell, who will
notice many ideas similar to those he propounded so eloquently in his
1974 Colloquium entitled, "General Psychiatry and Applications to Design
of Services" at the Northwestern University Medical School, Department
of Psychiatry; and my diligent research assistants, Sue Henry, Robert
Merrick and Tina Yanow, all of the Class of 1976 at the Northwestern
University School of Law, who persevered in the most tedious of tasks.
But my greatest debt is to Dr. John M. Davis, Research Director of the
Illinois Psychiatric Institute, who gave freely of his time, his facilities
and his publications; I trust he will disagree vigorously with much of
what I say and will forgive me for disregarding his better wisdom.
1. 422 U.S. 563 (1975).
2. 422 U.S. at 573.
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parens patriae power of the state, for involuntary confinement. 3
I have chosen drug treatment of schizophrenia for a number of
reasons. First, it puts the case for involuntary treatment of
the mentally ill in its most favorable light. It is a treatment
(1) that knowledgeable psychiatrists agree is one of the most
3. In the circuit court opinion, O'Connor v. Donaldson, 493 F.2d
507 (5th Cir. 1974), vacated, 422 U.S. 563 (1975), Judge Wisdom set out
the theory for such a justification. There are two permissible types of
commitments, he hypothesized: those under the police power, in which
the state confines people who might injure themselves or others, and
those under the parens patriae power, in which it confines the nondanger-
ous in order to give them needed psychiatric treatment. Id. at 520-27.
When the state commits someone under the parens patriae power, Wis-
dom proceeded, that person has a right to treatment; Donaldson was thus
entitled to damages because his commitment was of the second type,
and he had received no treatment at all. Id. at 531.
The Supreme Court saw no need to deal with either of these ration-
ales for commitment of the mentally ill. Since the jury had found Don-
aldson harmless, the confinement of dangerous persons was not at issue;
and since the jury had found that Donaldson received no treatment, there
was no reason to decide the parens patriae issue.
One might wonder why Judge Wisdom engaged in such an extensive
analysis, since it is clear that the Supreme Court's narrower approach
is quite adequate. The answer lies in the politics of decisionmaking in
the Fifth Circuit. In December of 1972, a few weeks after the jury's
verdict in the Donaldson case, lawyers argued a case, Wyatt v. Aderholt,
503 F.2d 1305 (5th Cir. 1974), which more clearly presented the right-to-
treatment issues to the Fifth Circuit. In Wyatt, Judge Frank Johnson of
the Middle District of Alabama had ordered the state of Alabama to re-
structure its entire mental health system so that those in the Alabama
state hospitals who were committed under the state's parens patriae
power would have at least some chance of receiving the treatment they
were confined to get. See Wyatt v. Stickney, 344 F. Supp. 373 (M.D. Ala.
1972). The case stalled on appeal, and when the Donaldson case was de-
cided some 16 months after the oral argument in Wyatt, 23 months after
the filing of the Wyatt appeal, Wyatt was still undecided. The Fifth Cir-
cuit finally decided Wyatt in November of 1974. Was there no right to
treatment for those in the Alabama hospitals as the appellants argued?
"This contention," the court responded, again through Judge Wisdom, "is
largely foreclosed by our decision, issued since the institution of this ap-
peal, in Donaldson v. O'Connor . . . ." Wyatt v. Aderholt, 503 F.2d
at 1312. It is fairly clear from this sequence that Wisdom, the
only judge who sat on both panels, saw that the way to break the im-
passe in Wyatt, which in part necessarily turned on the question of
whether there was a constitutional right to treatment, was to decide that
issue in the Donaldson case, which was clearly an easier case to decide.
The Supreme Court was aware that the Donaldson case had been
cited as precedent to decide Wyatt and a Georgia case that was argued
with it, Burnham v. Department of Public Health, 503 F.2d 1319 (5th
Cir. 1974), cert. denied, 422 U.S. 1057 (1975). The Supreme Court noted
in Donaldson that its decision deprived the Fifth Circuit's opinion of
precedential value, 422 U.S. at 578 n.12. This may have been more an
assertion of procedural propriety than of substance, since four days after
it decided Donaldson the Court declined to review the Burnham case.
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efficacious in psychiatry, (2) that is available at state mental hos-
pitals, and (3) whose dangers are small. Moreover, there is a sub-
stantial body of well-designed research examining its efficacy.
Finally, and perhaps most significant, schizophrenia is the most
prevalent disorder in our public mental health system. It
accounts for about half the patients in the system,4 and little,
if anything, more than a diagnosis of schizophrenia is necessary
for commitment in most mental health courts.5
The argument that treatment benefits ought to justify con-
finement looms as the single most important legal issue in com-
mitment of the mentally ill. Although the courts to date are
divided on the issue,0 and Donaldson gives no clue how the
4. See M. KRAMER, E. POLLACK, R. REDICK & B. LocKE, MENTAL
DISoRDER/SuicmE 64-67 (1972).
5. That this is true is clear to anyone who has watched a day's
hearings at a mental health court. State psychiatrists testify to a diag-
nosis and the judge commits the patient, with little else of substance
transpiring at the hearing. When statutes require there will be testi-
mony about the dangers attendant upon the disorder, but, as likely as
not, that testimony will be an inference from the diagnosis. See, e.g.,
Hough v. United States, 271 F.2d 458, 468 (D.C. Cir. 1959) ("any para-
noid schizophrenic is potentially dangerous"). Since few mental patients
ever litigate commitment proceedings strenuously enough to merit a pub-
lished opinion, the slender proof necessary for commitment is difficult
to document. For an example, however, of a reported case where appar-
ently nothing more than a diagnosis of schizophrenia was required to
commit a person, see In re Herold, 8 App. Div. 2d 905, 187 N.Y.S.2d 79
(3d Dep't 1959).
The evidence presented in other types of cases reveals that a diagno-
sis of schizophrenia may have a number of significant legal effects. See,
e.g., People v. Thasa, 32 N.Y.2d 712, 296 N.E.2d 804, 344 N.Y.S.2d 2 (1973)
(schizophrenic incompetent to waive Miranda rights); Boland v. State,
30 N.Y.2d 337, 284 N.E.2d 569, 333 N.Y.S.2d 410 (1972) (schizophrenia
is a disability which prevents tolling of statute of limitations); People
v. Childs, 51 Ill. 2d 247, 281 N.E.2d 631 (1972) (cannot presume one diag-
nosed schizophrenic is sane; such a person is entitled to an instruction
on insanity defense in murder trial).
6. One lower federal court, for example, has approved a forty-five
day confinement of the mentally ill without a hearing on the ground
that during that time "the medical staff at the hospital can adequately
alleviate [the patient's] mental illness. . . ." Logan v. Arafeh, 346 F.
Supp. 1265, 1269 (D. Conn. 1972), aff'd mem. sub nom. Briggs v. Arafeh,
411 U.S. 911 (1973). Accord, Fhagen v. Miller, 29 N.Y.2d 348, 278 N.E.2d
615, 328 N.Y.S.2d 393, cert. denied, 409 U.S. 845 (1972); cf. Robinson
v. California, 370 U.S. 660, 666 (1962) (dictum that compulsory treatment
of mentally ill, "involving quarantine, confinement, or sequestration," is
a permissible state function). The West Virginia supreme court, on the
other hand, has held involuntary confinement in the "best interest" of
the patient unconstitutional, noting that "society abounds with persons
who should be hospitalized, either for gall bladder surgery, back opera-
tions, corrective orthopedic surgery, or other reasons; yet, in these areas
society would not contemplate involuntary hospitalization for treat-
1976]
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Supreme Court would decide the issue, it is an argument that
psychiatrists are increasingly using to justify the present mental
health system. Alan Stone, Professor of Law and Psychiatry at
Harvard and Chairman of the American Psychiatric Association's
Commission on Judicial Action, is the most important repre-
sentative of this psychiatric view. Deeming predictions of dan-
gerousness too unsound a basis for commitment, he defines the
major issues in a commitment proceeding as whether a serious
mental illness is present, whether treatment is available, and
whether a reasonable man would accept that treatment.7 Since
courts rely to a very great extent on psychiatric opinions in for-
mulating mental health law, one can expect that the courts will
increasingly have to deal with this approach.
I. THE LEGAL FRAMEWORK
The Donaldson decision clearly affirmed the notion, implicit
in Jackson v. Indiana," that substantive due process governs com-
mitment of the mentally ill-that courts must balance the means
states use against the ends they hope to achieve. Jackson dealt
with the indefinite commitment of a retarded deaf-mute adjudi-
cated incompetent to stand trial for two robberies involving
goods whose total value was about nine dollars. In discussing
the due process implications of this procedure, the Court said
that "[a] t the least, due process requires that the nature and
duration of commitment bear some reasonable relation to the
purpose for which the individual is committed." 9 Since the state's
purpose for commitment was to render Jackson competent for
ment." State ex rel. Hawks v. Lazaro, 202 S.E.2d 109, 123 (W. Va. 1974).
Accord, Kendall v. True, 391 F. Supp. 413 (W.D. Ky. 1975); Lynch v.
Baxley, 386 F. Supp. 378 (M.D. Ala. 1974); Bell v. Wayne County General
Hospital, 384 F. Supp. 1085 (E.D. Mich. 1974); Lessard v. Schmidt, 349
F. Supp. 1078 (E.D. Wis. 1972), vacated on other grounds, 414 U.S. 473,
conforming order issued, 379 F. Supp. 1376 (1974), vacated on other
grounds, 421 U.S. 957 (1975).
7. A. STONE, MENTAL HEALTH AND LAW: A SYSTEM IN TRANSITION
(1975). Not all psychiatrists agree with Dr. Stone, see Peszke, Is Dan-
gerousness an Issue for Physicians in Emergency Commitments? 132 AM.
J. PsYczn T. 825 (1975), and some who seem to agree actually do not,
see Rachlin, Pam & Milton, Civil Liberties v. Involuntary Hospitaliza-
tion, 132 Am. J. PSYCHIAT. 189 (1975) (Article's thesis is that the "over-
riding right [of mental patients] is adequate treatment," but the mainjustification it gives for involuntary hospitalization is not that it is neces-
sary for treatment, but that the public is unwilling to accept the mentally
ill.). However, Stone's voice is clearly the most important in psychiatry
in this area.
8. 406 U.S. 715 (1972).
9. Id. at 738.
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trial, in order to sustain the commitment, the state would have to
demonstrate both a substantial probability of rendering Jackson
competent and actual progress toward that goal. Employing the
same process of reasoning, the Court in Donaldson, given the
jury's findings that Donaldson was not dangerous and had re-
ceived no treatment during his confinement, scrutinized "what
was left as justification for keeping Donaldson in continued con-
finement."'10 It rejected as "unjustified" custodial confinements
based upon a simple finding of mental illness, analogizing such
commitment to confinement intended to provide the patient a
higher standard of living, or to protect the public from exposure
"to those whose ways are different."" The label is not substan-
tive due process, but the process of analysis is.
The Donaldson opinion, then, has at least set the stage for
a thorough consideration of the question it declined to address.
To begin that analysis, one must deal first with three subordinate
questions: what are the relevant factors in the balancing process;
what should be the state's burden of proving that the balance
lies in favor of its interests; and what type of evidence should
be required to meet that burden?
A. THE RELEVANT FACTORS
Clearly, if treatment is to be the state's justification for in-
voluntary confinement of the mentally ill, some degree of ef-
ficacy in the proposed treatment is a sine qua non to justifying
the confinement. It is a necessarily justiciable issue, not one
which can be given over entirely to the psychiatrists' unreview-
able discretion. The Supreme Court said as much in a footnote
to the Donaldson opinion. Responding to Dr. O'Connor's argu-
ments that, despite the jury's finding that Donaldson was not
provided treatment, the Court must treat the adequacy of treat-
ment as a nonjusticiable question to be left to the discretion of the
psychiatric profession, the Court stated that "where 'treatment'
is the sole asserted ground for depriving a person of liberty, it
is plainly unacceptable to suggest that the courts are powerless
to determine whether the asserted ground is present.' 2
If the adequacy-or, better put, the efficacy-of treatment is
a justiciable issue when one is deciding the appropriateness of a
confinement, so too it should be when one is deciding the perhaps
10. 422 U.S. at 574.
11. Id. at 575.
12. Id. at 574 n.10.
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inseparable issue of whether to administer treatment to an uncon-
senting patient. I feel that the proposition that courts can and
must examine the efficacy of treatment underlies such cases as
Application of President and Directors of Georgetown College,
Inc.,13 and Jacobson v. Massachusetts,'14 leading cases for the
proposition that the state may treat an unwilling patient. In
Georgetown, Judge Skelly Wright of the United States Court of
Appeals for the District of Columbia ordered a lifesaving blood
transfusion to a patient who refused it on religious grounds;' 5 in
Jacobson the United States Supreme Court upheld the constitu-
tionality of a compulsory vaccination program. In neither case
did the court explicitly examine the efficacy of treatment (in
Jacobson the Court deferred to the legislative judgment; in
Georgetown the question was not addressed), but in each case
the treatment was widely known to be effective. Had this not
been the case the courts would have required evidence to support
the infringements upon personal autonomy.16 If, for example, the
13. 331 F.2d 1000 (D.C. Cir.), cert. denied, 377 U.S. 978 (1964).
14. 197 U.S. 11 (1905).
15. See also United States v. George, 239 F. Supp. 752 (D. Conn.
1965) (transfusion ordered for Jehovah's Witness father of four in critical
condition because of bleeding ulcer); John F. Kennedy Memorial Hospi-
tal v. Heston, 58 N.J. 576, 279 A.2d 670 (1971) (transfusion ordered for
incoherent Jehovah's Witness severely injured in automobile accident;
supreme court decision issued after transfusion completed); Powell v.
Columbian Presbyterian Medical Center, 49 Misc. 2d 215, 267 N.Y.S.2d
450 (Sup. Ct. 1965) (court overrode refusal, on religious grounds, of life-
saving transfusion).
One commentator, Byrn, Compulsory Lifesaving Treatment for the
Competent Adult, 44 FORDHAm L. REV. 1, 11 (1975), reports one contrary
case from a newspaper report. The case appears to be unique. An Illi-
nois case cited by Byrn for the proposition that the refusal of a transfu-
sion must be sustained, where no circumstances establish a compelling
interest in preserving the life of a competent adult patient for the welfare
and safety of others, was decided after the transfusion had been ordered
by the lower court and given. In re Estate of Brooks, 32 Ill. 2d 361,
205 N.E.2d 435 (1965). Hence the court did not itself face the life-or-
death choice and could exercise its intellectual inclinations with impu-
nity. There were other aspects of the case that might also have influ-
enced the court, such as the fact that despite the transfusion Mrs. Brooks
died, or that the guardian was appointed without notice to Mrs. Brooks
or her family. Moreover, the court viewed Mrs. Brooks as a competent
adult. Byrn says that "[t]he trend in the law favors Brooks," but the
cases cited above would at least seem to indicate that the courts are di-
vided.
16. In Jacobson, moreover, the Court did say that it assumed no
one would be vaccinated who was not "a fit subject of vaccination." 197
U.S. at 37. The Court must have meant by this that only those who
would benefit by the vaccination would receive it (for example, that it
would not be forced on those who, by virtue of having already had
1154
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danger in Georgetown had been death by cancer and the pro-
cedure advised had been a radical mastectomy, a procedure whose
benefits are more speculative than the benefits of a transfusion
to someone who has lost a great deal of blood, the decision might
have been quite different.
1 7
In the legal context, the concept of efficacy is a complex one;
it is not simply a question of curing or not curing, but subsumes
two subquestions: how likely it is that the treatment will bene-
smallpox, had a natural immunity to the disease). Hence, the Court rec-
ognized that the efficacy of the treatment must be considered. The other
possible interpretation of the quoted phrase-that "fit" meant one whose
health would be unimpaired by vaccination-cannot have been what the
Court intended, for it went on to discuss disjunctively the threat vacci-
nation might pose to a person's health.
At least one recent case has adopted the view that "treatability" is
a prerequisite to civil commitment. Lynch v. Baxley, 386 F. Supp. 378,
391 (M.D. Ala. 1974). Some psychiatrists, too, have advocated this posi-
tion. See, e.g., Peele, Chodoff & Taub, Involuntary Hospitalization
& Treatability: Observations from The District of Columbia Experience,
23 CATH. U. L. REV. 744, 750-53 (1974); Redich & Mollica, Overview:
Ethical Issues in Contemporary Psychiatry, 133 Aim. J. PsYcHiAT. 125,
129 (1976).
17. A noteworthy decision in this regard is Kaimowitz v. Depart-
ment of Mental Health, Civil No. 73-19434-AW (Wayne County Cir. Ct.
Mich. July 10, 1973), reprinted in 2 LEGAL RIGHTS oF THE MENTALLY
HANDICAPPED 785 (B. ENNIS & P. FRIEDmAN, ed. 1973) [hereafter cited
as LEGAL RIGHTS], forbidding a mental patient to consent to various psy-
chosurgical techniques intended to eliminate the patient's traits of sexual
psychopathy, a treatment of unknown efficacy and possible danger.
The court concluded that the program proposed was "clearly experi-
mental, pose[d] substantial danger to research subjects . . . carrie[d]
substantial unknown risks," id. at 799, and promised no benefit to either
subject or society. It forbade the experiments because "informed consent
cannot be given by an involuntarily detained mental patient. . . ." Id.
at 803. Much of the Kaimowitz opinion, however, and much of the trial,
were spent on the question of whether psychosurgery is an effective form
of treatment, and the court, in sunning up, emphasized that once "the
type of psychosurgical intervention proposed here becomes an accepted
neurosurgical procedure and is no longer experimental, it is possible,
with appropriate review mechanisms, that involuntarily detained mental
patients could consent to such an operation," id. at 820 (footnote omit-
ted). Since the medical acceptability of psychosurgery would not
change the quality of John Doe's consent, it appears that evidence of
a lack of efficacy and of safety-and not evidence of a lack of consent-
was the determinative factor for the Kaimowitz court.
For other cases where courts had to closely examine a specific mode
of treatment (to use the term loosely) and fashion a fairly specific rem-
edy, see Nelson v. Heyne, 491 F.2d 352 (7th Cir. 1974) (specific regula-
tion of use of tranquilizing drugs); Knecht v. Gillman, 488 F.2d 1136,
1140-41 (8th Cir. 1973) (specific regulation of the use of apomorphine
in Iowa Security Medical Facility); cf. Wyatt v. Aderholt, 368 F. Supp.




fit the patient, that is, What percentage of a treated sample will
improve, and among those who improve, how great that improve-
ment will be. Both of these are important in evaluating the treat-
ment we impose on an unwilling patient. If the improvement is
great but the success rate is low, we may hesitate to force some-
one to undergo the treatment; similarly, we may decline to force
someone to undergo a treatment of almost certain success for a
trivial disorder-as, for example, ordering someone to take an
aspirin for a headache. These two factors, however, are not the
only considerations. Another clearly relevant factor in the
balancing process must be the danger to the patient from the
proposed treatment. If we are to confine a person against his
will solely to cure him of mental illness, surely it will not do to
inflict upon him some equivalent or greater (or perhaps even
lesser) harm or expose him to some significant risk of harm.
The treatments in both Georgetown and Jacobson, it is worth
noting, were commonly known to be quite safe.
Finally, the treatment must prevent some foreseeable, ser-
ious danger, either to the patient or to society. In George-
town, while Judge Wright adduced a number of bases for his
decision, including the inaudibility of the patient's answers when
asked if she wanted the transfusion and the fact that her infant
child would have been left without a mother, "[t]he final and
compelling reason for granting the emergency writ," he wrote,
"was that a life hung in the balance."' 8  And in Jacobson, the
vaccination was both to protect the patient from smallpox and
society at large from an epidemic. 19
18. 331 F.2d at 1009.
19. Since the question raised but left unanswered by the Donaldson
Court was the power of the state to confine and treat a nondangerous
mental patient and the question that I will deal with is the treatment
of the nondangerous schizophrenic, it is necessary for me to explain how
the issue of dangerousness even arises. In the first place, by nondanger-
ous I mean those schizophrenics who have not been shown on the basis
of some substantial evidence from their individual history to be more
likely than the average person to commit some dangerous act. When
the issue of dangerousness arises at the commitment stage, the typi-
cal evidence of dangerousness is a psychiatrist's clinical judgment that
the patient will do one of a number of dangerous things-for example,
assault someone, see, e.g., People v. Sansone, 18 Ill. App. 3d 315, 309
N.E.2d 733 (Dist. Ct. 1974), or maim himself, see, e.g., Mayock v.
Martin, 157 Conn. 56, 245 A.2d 574 (1969)-within a reasonable period
of time. Such judgments are most often based on the recent behavior-
either physical or verbal--of the patient, and may be quite independent
of the diagnosis of mental illness. See text accompanying note 179 infra.
Excluding this type of dangerousness does not exclude an examination
1156 [Vol. 60:1149
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To summarize, I suggest that there are four factors to be
examined in determining the permissibility of involuntary treat-
ment: (1) the likelihood of improvement: what the chances are
that the patient will improve; (2) the scale of improvement: how
much he will improve: (3) the dangers attendant on treatment;
and (4) the dangers attendant on failing to treat.
B. THE BURDEN ON THE STATE
The next question is what burden the state carries to support
its decision to confine to treat. One respected author has argued
that all the state need show in order to justify "governmental
intrusions upon human liberty [are] plausible arguments in sup-
port of the intrusions imposed. '20 I would suggest, on the other
hand, that the state must show a compelling need for the pro-
posed intrusion. Involuntary treatment is inseparable from
involuntary confinement in a mental hospital.21  Not only do
courts treat the two as one-courts rarely order treatment with-
out hospitalization, 22 and the order for commitment, even when
it says nothing about treatment, is generally thought to imply
an order to administer treatment-but, in practical terms, there
simply can be no involuntary treatment without involuntary hos-
of allegedly dangerous characteristics of schizophrenics as a class: that
they commit more crimes, that they are more often unable to take care
of themselves or that they less frequently hold steady jobs than non-
schizophrenic persons. Insofar as many justify commitment of the non-
dangerous schizophrenic on the basis of these putative characteristics
of schizophrenics as a class, I will find it necessary to discover whether
these characteristics exist and whether drug treatment has any effect
on them.
20. Tribe, Foreward: Toward a Model of Roles in The Due Process
of Life and Law, 87 HARV. L. REv. 1, 17 (1973).
21. The two may involve different considerations, and commenta-
tors have differed over whether it is worse to be jailed or to be shot
full of drugs. See Shapiro, Legislating the Control of Behavior Con-
trol: Autonomy and the Coercive Use of Organic Therapies, 47 S. CAL.
L. REV. 237, 280-81 n.147 (1973) and sources cited therein. A recent de-
cision of the Minnesota supreme court, barring a damage suit for elec-
troconvulsive treatment given to a minor without consent, considered
that the decision to undergo hospitalization was a "more fundamental
decision" than the decision to give treatment. Price v. Sheppard, 239
N.W.2d 905, 911 (Minn. 1976). The court's approach, however, was
based on its assumption that the fact of commitment implied that the
minor was unable to act rationally for himself. Id.
22. The suggestions of Lake v. Cameron, 364 F.2d 657 (D.C. Cir.
1966) and Chambers, Alternatives to Civil Commitment of the Mentally
Ill: Practical Guides and Constitutional Imperatives, 70 MzCH. L. REV.
1107 (1972), that courts limit themselves to the least restrictive therapeu-
tic alternative have, for the most part, fallen on deaf judicial ears.
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pitalization. If a patient is free to walk out the door of the hos-
pital, then he is also free, by so doing, to refuse treatment. We
are faced, then, with the Supreme Court's categorization of in-
voluntary confinement in an institution as a "massive curtail-
ment of liberty,"23 and with its conclusion that where physical
liberty is at stake, such "'evidence as would suffice in a civil
case' " 24 is not sufficient. Hence, proving the reasonableness
of treatment-the analogue of proving a criminal act by the
preponderance of the evidence-should be insufficient where
the treatment necessarily entails confinement.
Recently, however, in response to criticism of involuntary
psychiatric treatment, both legal 25 and psychiatric26 commenta-
tors have taken the position that the refusal of treatment by a
mentally ill person may be overridden if he lacks "the mental
23. Humphrey v. Cady, 405 U.S. 504, 509 (1972).
24. In re Winship, 397 U.S. 358, 363 (1970) (juvenile delinquency
proceeding) (quoting from the dissenting opinion in the court below, W.
v. Family Court, 24 N.Y.2d 196, 205, 247 N.E.2d 253, 259, 299 N.Y.S.2d
414, 422 (1969).
In one recent case that has travelled to the Supreme Court several
times, the Court has hinted that it considers mental health proceedings to
be at least "quasi-criminal." In Lessard v. Schmidt, 349 F. Supp. 1078
(E.D. Wis. 1972), vacated, 414 U.S. 473, conforming order issued, 379 F.
Supp. 1376 (1974), vacated, 421 U.S. 957 (1975), the district court ordered
that the mental health courts of the state of Wisconsin follow certain con-
stitutional guidelines in their adjudications. In the case's most recent re-
turn to the Supreme Court, the Court vacated and remanded to the dis-
trict court, Schmidt v. Lessard, 421 U.S. 957 (1975), in light of Huffman
v Pursue, 420 U.S. 592 (1975), which, on the principles of Younger v.
Harris, 401 U.S. 37 (1971), forbade federal courts from interfering in
pending state proceedings which were "akin to a criminal prosecution."
420 U.S. at 604. Hence the Court must at least incline towards the view
that commitment proceedings are "akin to a criminal prosecution."
25. Developments in the Law-Civil Commitment of the Mentally
Ill, 87 HARv. L. Rnv. 1190, 1213-14 (1974) [hereafter cited as Develop-
ments].
26. "Unfortunately, a small percentage of patients who need hos-
pitalization are unable, because of their mental illness, to make a free
and informed decision to hospitalize themselves. Their need for and
right to treatment in a hospital cannot be ignored." Board of Trustees
of the American Psychiatric Ass'n, Position Statement on Involuntary
Hospitalization of the Mentally Ill, 130 AM. J. PSYCHIAT. 392 (1973).
See also Peszke, Is Dangerousness an Issue for Physicians in Emer-
gency Commitment? 132 AM. J. PSYcHAT. 825, 827 (1975) ("not com-
mitting a nondangerous mentally ill individual who is incapable of
making rational decisions and could benefit from treatment is analogous
to not hospitalizing an unconscious accident victim who is unable to ask
for help but is not dangerous"). But cf. Redlich & Mollica, supra note




capacity to determine the desirability of obtaining care" 27 and
the benefits of treatment outweigh the detriments; or put
another way, that the state may ignore a refusal of confinement
and treatment where "a reasonable man in this situation [would]
give up this much freedom for this much treatment."28
While this approach seems quite plausible at first hearing,
it is unsound. The idea of "incompetence" on which this view
relies is not sensitive to the human realities involved. It treats
the mind as a machine; if it malfunctions, we simply ignore its
product-here, the refusal. But the mind is not a machine, nor
are psychiatrists mechanics who have any clear notion of what
happens inside the mind. Their conclusions-and it is they who
are generally considered the "experts" in this area, they to whom
courts will defer-are based not on any knowledge about how
the mind works, but on their opinion that the responses of the
person are not rational. Psychiatrists' testimony tends to be
characterized by statements "regarding instances of the individ-
ual's failure to speak or behave rationally, with particular atten-
tion to the reasons which the individual espouses for refusing
hospitalization." 29  Consonant with this logic, if the person in
question refuses hospitalization for reasons that a psychiatrist
finds frivolous, or simply unpersuasive, the state should override
the patient's refusal of hospitalization or treatment.
This approach does not square with the deference usually
accorded a patient's wishes. Georgetown and Jacobson are
27. Developments, supra note 25, at 1213-14. If by this the editors
meant to include only those who could make no expression of assent
or protest, their test poses no particular problem. Our jurisprudence
routinely ignores the lack of consent of a patient who is unable to com-
municate his or her consent to, or refusal of, treatment. Normally these
cases arise where, for one reason or another, the person lacks the physi-
cal capacity to communicate, perhaps because he is unconscious-this is
the typical emergency room situation-or is a human vegetable who
makes no discernible response to our questions, however phrased. In
these cases we follow our judgment because we have no other choice
and try to substitute what we feel would have been the patient's judg-
ment. In civil commitment cases, this category would perhaps include
the catatonic who does not respond to questions put to him. But it is
clear that the comment means to go a great deal further than this: it
would have us determine whether someone is "incapable of rational deci-
sionmaking." Id. at 1214. The Minnesota supreme court recently
adopted this unsound approach, Price v. Sheppard, 239 N.W.2d 905, 911
(quoting Developments, supra), but its concern with the "necessity and
reasonableness of the means utilized by the state" as well as the possible
dangers involved, id. at 911-12 seem to parallel the concerns embodied in
the four factors discussed in the text.
28. Stone, Comment, 132 AM. J. PSYCHIAT. 829, 830 (1975).
29. Developments, supra note 25, at 1301.
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clearly exceptions to the norm: physicians and judges usually
honor a patient's refusal of treatment, no matter how trivial the
reason for refusal. There is no good reason to deviate from this
position when we are dealing with the mentally ill. In a recent
case, for example, a court refused to override a mental patient's
"irrational but competent" refusal to undergo breast surgery for
cancer; that the reasons for the refusal were unsound was con-
sidered immaterial.3 0 If the law requires consent out of respect
for the dignity and autonomy of the individual, that interest can
be no less significant when the individual is a mental patient; if
the interest does diminish, then we are saying that the mental
patient is less a human being than others. Consent is not simply
a question of who knows better what will happen, or what the
risks are; the doctor is generally a better judge of that than the
patient is. But since the patient will suffer the consequences,
since he bears the risk of mischances, he should have the power
to make the decision.
Because of the inevitable loss of liberty involved in involun-
tary treatment and out of a respect for the human dignity of the
patient, courts ought to consider treatment in the face of refusal,
even a refusal by a mentally ill person, to be the rare exception
and not the rule-an exception to be established only by a demon-
stration that, upon a balancing of the factors previously discussed,
the state's interest in treatment is compelling.
C. THE ADMISSIBLE EVIDENCE
The final issue to be addressed in establishing a legal frame-
work is the type of evidence that should be required of the state
in its attempt to establish the necessity of treatment in particular
cases. If we require the state to make its case a compelling one,
surely it ought not be permitted to make its case on the basis of
shoddy evidence.
Let us consider, for illustration, what evidence ought to be
adduced to prove the likelihood and scope of improvement.
Opinions arising out of the unsystematic clinical experience of
psychiatrists, psychologists, and others who labor among the
mentally ill should not by themselves be enough to prove the
effectiveness of a method of treatmentA' The reasons for this
30. In re Yetter, 62 Pa. D. & C.2d 619, 624 (Northampton City Ct.
1973), criticized in Friedman, Legal Regulation of Applied Behavior
Analysis in Mental Institutions and Prisons, 17 ARiz. L. REv. 39, 79
(1975).
31. For a discussion of many of the reasons why clinical judgments
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are numerous. The psychiatrist's opinion of whether his patient
is better cannot be an unbiased judgment; it may be highly
colored by what he thinks the patient ought to be. His evalu-
ation of the patient's improvement may simply be a reflection
of the fact that, after long contact with him, the patient now
agrees with the psychiatrist's outlook on life. The patient, on
the other hand, may be deceiving the psychiatrist. If the psy-
chiatrist has no source of information other than the patient's
own report about himself, he may know nothing about how the
patient really gets along in the world. Also, the psychiatrist may
remember his successes better than his failures. Or, perhaps un-
consciously, he may have picked for treatment patients who
would respond well to the treatment or who might have im-
proved on their own.
The biases built into the clinical observations of psychiatrists
have led to a tendency toward "faddishness" in psychiatric treat-
ment. A few observers report spectacular results on a few
patients with a new kind of treatment; others report similar
findings.32  Quickly the treatment method becomes standard
practice until, sometime later, more careful observers note that
their patients seem no better and maybe a little worse because
of the treatment. The use of lobotomy for schizophrenics during
the fifties is an example of a once standard therapy that psy-
chiatrists now think worthless or worse.
Unless we wish merely to perpetuate the errors of the psy-
chiatric profession, we must ask for something sounder than
subjective clinical experience to justify a treatment method.
Objective research has been done on the efficacy of psychiatric
treatment, and it is there that we must turn if we hope to justify
our system of involuntary treatment. Of course not every piece
in general are unreliable, see Ennis & Litwack, Psychiatry and the Pre-
sumption of Expertise: Flipping Coins in the Courtroom, 62 CALIF. L.
REv. 693, 719-34 (1974).
32. One of the most notable examples of this "faddishness" occurred
during the 1830's and 1840's, when the directors of mental hospitals
claimed 80, 90 and even 100 percent cure rates among their charges.
Their statistics were the most persuasive evidence in convincing legisla-
tures to build mental hospitals. In the end it turned out that the people
claiming high cure rates had manipulated their statistics in the most out-
rageous ways. In calculating a cure per patient ratio, for example, doc-
tors counted a patient who had been "cured" more than once (a rela-
tively common occurrence) as multiple cures, but retained the denomina-
tor of only one patient. One historian concluded that institutional heads
perpetuated this sort of misrepresentation "in order to stay abreast of
their fellow practitioners who were doing the same thing." A. DEUTSCH,
THE MENTALLY ILL iN AmERICA 133 (1949).
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of published research should be given equal weight.8 8 We should
require two things of all research on which we base our decisions:
(1) adequate experimental design, and (2) replication of results.
Those two elements are the soul of the scientific method.
If there is a flaw in experimental design, we cannot be sure
that the experimental result is due to the hypothesized cause.
Some researchers have noted, for example, that poorly designed
experiments on the efficacy of psychoactive drugs produce a
significantly higher cure rate than those with a tight design.34
One may speculate on the reasons for this. My own preference
is that there is an unconscious bias in the researcher, who knows
that greater glory belongs to the discoverer than to the debunker,
and that this bias appears in the experimental results because
of the lack of proper controls. But whatever the reason, we
should be suspicious of the positive results of poorly designed
research.
33. See, e.g., Staudt & Zubin, A Biometric Evaluation of Somato-
therapies on Schizophrenia, 54 PSYCHOL. BULL. 171 (1957):
In reviewing the vast literature of therapeutic results one finds
conflicting reports ranging from severe skepticism of the various
theraloies to inordinate enthusiasm for them. Consequently, ev-
ery clinician can cite a study to support his particular viewpoint
on any given therapy.
34. Foulds, Clinical Research in Psychiatry, 104 J. MENT. SC. 259
(1958) (survey of 72 British and American studies: 25 percent of con-
trolled experiments showed positive therapeutic results; 83 percent of un-
controlled experiments showed positive therapeutic results): Fox, The
Investigation of the Effects of Psychiatric Treatment, 107 J. MENT. SCi.
493 (1961) (57 articles: where experimental design acceptable, 54 percent
positive; where unacceptable, 91 percent positive). See also Glick & Mar-
golis, A Study of the Influence of Experimental Design on Clinical Out-
come In Drug Research, 118 AM. J. PsYcHrAT. 1087 (1959) (single-blind
experiments produce significantly more positive results than dou-
ble-blind experiments, but other differences between the two types of
experiments, such as length of treatment and use of placebo, make infer-
ences difficult to draw). The perception that uncontrolled studies show
better results than controlled studies seems to be shared by most drug re-
searchers. Hollister's group referred to one case in which their research
revealed "a situation almost unique in clinical psychopharmacology, in
which a drug has looked better in a controlled than in an uncontrolled
study." Hollister, Overall, Caffey, Bennett, Meyer, Kimbell & Honigfeld,
Controlled Comparison of Haloperidol with Thiopropazate in Newly Ad-
mitted Schizophrenics, 135 J. NERv. & MENT. Dis. 544, 548 (1962). Klein
and Davis have pointed out that in the case of chlorpromazine and re-
lated drugs "studies showing methodological difficulties tend to find
drugs ineffective," D. KLEIN & J. DAvIs, DIAGNOSIS AND DRUG TREATMENT
OF PSYCHIATRIc DISORDERS 55 (1969) [hereafter cited as KLEIN & DAvIS],
but they generally agree that "uncontrolled studies frequently give en-
thusiastic reports about drugs which subsequent double-blind evalua-
tions show to be useless." Id. at 52.
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Replication is necessary to reduce the likelihood that the first
result was pure chance-for example, that the treatment was
tried on a group of people who were going to get better the next
week anyway-and to rule out the possibility of conscious or
unconscious cheating. In the present world of academic medi-
cine, where most psychiatric research is done, there is great pres-
sure to produce results, which may lead to fakery.35 Financial
motives also intrude. For example, the pharmaceutical industry
finances most of the psychiatric drug research in this country.
Research money may flow with greater regularity to those whose
research shows more positive results, and even the fear of such
discrimination may influence a research scientist.
In the past, the courts have been regrettably reluctant to
examine carefully the efficacy of treatment provided to the in-
voluntary patient. Most significantly, the right-to-treatment
cases, which rest on the theory that if the state deprives one
of his liberty on the ground that he needs treatment, it must
provide that treatment, have generally been content to ensure
that treatment will be provided without questioning the poten-
tial success of the proposed treatment.8 6 This is particularly dis-
35. The scandal at the Sloan-Kettering Institute is perhaps the best-
publicized research fraud in recent times. There a researcher who was
trying to discover ways to defeat the body's rejection of foreign tissue,
a discovery which would greatly aid organ transplants, colored the
coats of mice in his experiment and claimed that the colored hair had
been transplanted from other mice. The researcher tried to explain his
actions by pointing to the pressures on him to produce research results.
See TIME, April 29, 1974, at 67; June 3, 1974, at 60; June 10, 1974, at 70.
36. The first right-to-treatment case, Rouse v. Cameron, 373 F.2d
451 (D.C. Cir. 1966), set the tone for subsequent litigation. There the
Court of Appeals for the District of Columbia, per Judge Bazelon, held
that Mr. Rouse, who four years earlier had been found not guilty by
reason of insanity of a crime with a one year maximum sentence and
thereafter committed to a hospital, had a statutory right to receive treat-
ment while incarcerated. Judge Bazelon, obviously reluctant to deal
with someone else's expertise, wrote:
According to leading experts "psychiatric care and treat-
ment" includes not only the contacts with psychiatrists but also
activities and contact with the hospital staff designed to cure or
improve the patient. The hospital need not show that the treat-
ment will cure or improve him but only that there is a bonafide effort to do so. This requires the hospital to show that ini-
tial and periodic inquiries are made into the needs and condi-
tions of the patient with a view to providing suitable treatment
for him, and that the program provided is suited to his particular
needs. Treatment that has therapeutic value for some may not
have such value for others. For example, it may not be assumed
that confinement in a hospital is beneficial "environmental ther-
apy" for all.
The effort should be to provide treatment which is adequate
in light of present knowledge. Some measures which have ther-
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appointing in view of the fact that, although the attorneys ar-
guing these cases have urged courts not to go so far as to say
that treatment alone will justify institutionalization of a mental
patient,87 courts, including the federal appellate court in Donald-
son,-38 have nonetheless taken this step,39 apparently on the
theory that society may confine people for their own good and
treat them against their will.40
apeutic value for the patient may be too insubstantial in compar-
ison with what is available. On the other hand, the possibility
of better treatment does not necessarily prove that the one pro-
vided is unsuitable or inadequate.
Id. at 456-57 (footnotes omitted, emphasis added).
Medical observers, with an almost audible sigh of relief, read
this language, particularly the italicized sentence, to mean that the hos-
tal need not prove that its treatment is effective. See Cameron, Non-
medical Judgment of Medical Matters, 57 GEO. L.J. 716, 720-21 (1969).
Although the second paragraph seems to imply that some broad notion of
effectiveness inheres in the "bona fide effort" that the hospital must
make, on the whole this is an accurate reading of the passage.
The courts are not alone in declining to examine the psychiatrist's
expertise with regard to the efficacy of psychiatric treatment. Commen-
tators have relied on pat, published statements on the effect of psychiatric
drugs in evaluating whether the state should treat involuntary patients
over their refusal of treatment. See, e.g., Schwartz, In the Name of
Treatment: Autonomy, Civil Commitment, and Right to Refuse Treat-
ment, 50 NOTRE DAME LAW. 808, 812-13 (1975); Shapiro, Legislating
the Control of Behavior Control: Autonomy and the Coercive Use of
Organic Therapies, 47 S. CAL. L. REV. 237, 244-46 & nn. 9, 10, 76, 88,
& 91 (1974); Comment, Forced Drug Medication of Involuntarily Com-
mitted Mental Patients, 20 ST. Louis L.J. 100, 111-12, 116 (1975); Note,
Conditioning and Other Technologies Used to "Treat?" "Rehabilitate?"
"Demolish?" Prisoners and Mental Patients, 45 S. CAL. L. REV. 616,
625-26 (1972). Unlike the courts, the majority of commentators have
opposed such treatment. Their reliance on overbroad statements about
psychotropic drugs, however, undermines their argument. Psychiatrists
simply ignore them because of their obvious ignorance of the relevant
psychiatric literature. I think that the case can be made against in-
voluntary treatment with psychotropic drugs, but if one is to convince
those who administer the system, the psychiatrists, one must familiarize
oneself with their literature.
37. See Brief for Respondent at 58 n.61, O'Connor v. Donaldson, 422
U.S. 563 (1975).
38. 493 F.2d at 522.
39. The step may be taken silently. One court, for example, re-
quired patient consent to treatment only in the case of "unusual or haz-
ardous" procedures, implying that consent was not necessary for other
procedures. Wyatt v. Stickney, 344 F. Supp. 373, 380, app. A, par. 9
(M.D. Ala. 1972).
Some courts have refused, as indicated above, to sanction confine-
ment of nondangerous mentally ill persons. See note 6 supra and accom-
panying text.
40. Although most lawyers who have litigated right-to-treatment
cases categorically deny that the right-to-treatment precludes a right-
to-refuse-treatment, see, e.g., Friedman & Halpern, The Right to Treat-
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One explanation for the hesitancy to examine efficacy may
be that these cases have dealt almost entirely with institutions in
which no treatment was offered or the treatment offered was
a patent farce.41 In the major lawsuit in the area, Wyatt v.
ment, in 1 LEGAL RIGHTS, supra note 17, at 273, 290-91, the denial is not
particularly persuasive. Let us, for purposes of argument, separate the
issues of confinement and treatment and examine some of the problems
that arise with the right-to-treatment if we also accept a right-to-refuse-
treatment. If, for example, an involuntary patient refuses to take the
drugs that the hospital offers him, can the hospital both honor that re-
fusal and continue to hold him against his will? If it cannot, is he really
held involuntarily, since by the act of refusing he gets out? And if he
is not held involuntarily, then the key element in all right-to-treatment
cases, confinement, is missing. If the hospital can keep him although
he refuses treatment, then is that any different, in actual effect, from
keeping him without treatment? Would it not be cruel and unusual to
punish someone for his failure to consent to treatment by keeping him
locked up? Is it less cruel and unusual to require the doctors to make
significant efforts to convince the patient to consent to treatment? The
trial judge in Donaldson, 493 F.2d at 531, apparently feeling that a pa-
tient's refusal of treatment that others felt was good for him was enough
to excuse the others from personal liability for confining him without
treatment, instructed the jury that Mr. Donaldson could not recover dam-
ages for those periods when he refused proferred treatment. The plain-
tiff did not appeal this instruction, so the issue was not before the Su-
preme Court. See also Whitree v. State, 56 Misc. 2d 693, 290 N.Y.S.2d
486 (Ct. Cl. 1968) (holding that doctors who honored plaintiffs re-
fusal to receive drugs were acting in a manner that was "illogical, un-
professional and not consistent with prevailing medical standards").
Contra, Winters v. Miller, 446 F.2d 65 (2d Cir.), cert. denied, 404 U.S.
985 (1971) (giving medication to unconsenting Christian Scientist states
a cause of action under 42 U.S.C. § 1983).
41. In Donaldson v. O'Connor, 493 F.2d 507, 511 (5th Cir. 1974), va-
cated, 422 U.S. 563 (1975), the court found that one defendant-psychia-
trist's claim that Mr. Donaldson had received "recreational" and "reli-
gious" therapy "amounted" to the fact that Donaldson had been allowed
"to attend church and engage in recreational activities, privileges he
probably would have been allowed in a prison." The court likewise
found that "milieu therapy" "was nothing more than keeping Donaldson
in a sheltered hospital 'milieu' with other mental patients; the defendants
did not refer to anything specific about the 'milieu' that was in any spe-
cial way therapeutic." See also In re Maddox, 351 Mich. 358, 88 N.W.2d
470 (1958) (rejecting the argument that prison is therapy for sexual
psychopaths).
There are some curiously disingenuous cases which justify lengthy
incarceration with apparently ineffective treatment because of the exper-
imental nature of the program. In State ex rel. Blunt v. Narcotic Addic-
tion Cont. Comm'n, 58 Misc. 2d 56, 295 N.Y.S.2d 276 (Sup. Ct.), aff'd
mrem., 31 App. Div. 2d 718, 296 N.Y.S.2d 533 (1st Dep't 1968), aff'd mem.,
24 N.Y.2d 850, 248 N.E.2d 918, 301 N.Y.S.2d 89 (1969), an addict who was
convicted of a misdemeanor with a one year maximum sentence was
committed to Rikers Island with other criminal addicts and nonaddicts
under a statute permitting a three-year incarceration for treatment of
addiction, and thereafter sought a writ of habeas corpus. He showed
that only 50 percent of the addicts at Rikers Island participated in the
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Stickney,42 plaintiffs argued that if certain conditions did not
exist-a humane environment, adequate treatment plans and
record-keeping for every patient, and an adequate staff-treat-
ment was not possible. It is not surprising, then, that the court's
order tried to establish these conditions and said virtually nothing
about the sufficiency of the treatment provided.43
In any event, it should now be apparent, after Donaldson,
that, at least where treatment is the sole justification for con-
finement of the mentally ill (assuming again, that it can be the
treatment program and that the program's only "therapy" consisted of
group meetings led by other criminal addicts. The court termed these
meetings "motivational rather than rehabilitative; their main purpose
being to engender in the addict a sincere desire to break his habit, change
his way of life, and accept rehabilitation," 58 Misc. 2d at 60, 295 N.Y.S.2d
at 279. Of the 600 addicts who had been committed to Rikers Island
"only 20-25 addicts had progressed sufficiently to the point where they
may be deemed tentatively 'cured.'" Id. at 61, 295 N.Y.S.2d at 280. None-
theless the court denied habeas because "[t]he experimental nature of
this program is obvious, and trial and error must be permitted if an ef-
fective and efficient program is to be evolved." Id. at 64, 295 N.Y.S.2d
at 282. That in all likelihood Mr. Blunt would be required to spend three
years in a prison instead of one, so that the state might experiment on
him, seemed not to disturb the judge.
Director of Patuxent Inst. v. Daniels, 243 Md. 16, 42, 221 A.2d 397,
412 (1965), cert. denied, 385 U.S. 940 (1966), similarly held that the court
could not interfere with Maryland's institution for defective delinquents,
which had produced precious few cures (apparently 162 out of 581 cases)
in its ten years of operation, "until its ineffectiveness is clearly demon-
strated," because the system was "an experimental one." One notable
tribunal has held that, in experiments involving human subjects, "[t]he
voluntary consent of the human subject is absolutely essential." United
States v. Karl Brandt, in 2 TRIALs OF WAR CRnV. 181 (Nuremberg Mil.
Trib. 1947). Certainly if one wished to conduct the "experiments" at
Rikers Island and Patuxent, one could get appropriate volunteers from
the prison population. Those subjects, while their consent might not be
all that one might hope for, would at least have finite terms of confine-
ment. Irrespective of their criminal sentences, the guinea pigs in Patux-
ent remain confined until the "experiment" is successful.
42. 344 F. Supp. 373 (M.D. Ala. 1972), modified sub nom. Wyatt
v. Aderholt, 503 F.2d 1305 (5th Cir. 1974).
43. Judge Johnson's order did put some limitations on the types
of treatment that could be used: no "unnecessary or excessive medica-
tion," 344 F. Supp at 380, app. A, f 6 (M.D. Ala. 1972); no "physical
restraint and isolation," except in emergencies, id. at 7; no "experi-
mental research without express and informed consent," id. at 8; and
no "procedures such as lobotomy, electro-convulsive treatment, adver-
sive [sic] reinforcement conditioning or other unusual or hazardous
treatment procedures without express and informed consent," id. at 9.
Other courts issuing orders governing the running of institutions have
followed the same general pattern. See, e.g., Martarella v. Kelley, 359




sole justification 44 ), the courts must examine the efficacy of the
treatment in order to ensure that the patient is not being de-
prived of liberty without due process of law.4 5 The remainder
of this Article is in large measure devoted to demonstrating the
sort of analysis of efficacy that a court should undertake.
II. DRUG TREATMENT OF SCHIZOPHRENIA
I have already outlined why I choose to focus upon drug
treatment of schizophrenia.46 Some elaboration is now in order.
As indicated above, one reason for my choice is the large body
of well-designed research on this topic. The research on drug
treatment is generally superior to that concerning other types
of treatment, because it is possible to do drug studies double
blind-that is, with patients randomly assigned to different
physically identical drugs, or to drug and identical placebo-so
that neither patient nor psychiatrist knows who is receiving what
medication. This design ensures that the expectations of neither
patient nor researcher will influence the perception of the drug
effect. Drug treatment is also the only psychiatric area in which
enough research exists to draw valid conclusions. As one of the
most respected of psychiatric research scientists put it:
Assessment of the relative value of the different forms of treat-
ment for the schizophrenic condition runs into [a] major prob-
lem . . . [w]ith the exception of drug-effect studies, the abun-
dance of opinion and prejudice is equalled only by the dearth
of scientific evidence.4 7
Primarily because of this lack of adequate research, I do
not intend to deal with psychotherapy, which essentially consists
of letting people talk themselves out of their psychological
dilemmas. Not only is the efficacy of psychotherapy problem-
atical,48 it is probably unprovable.49 More important, patients in
44. See text accompanying note 6 supra.
45. See text accompanying note 12 supra.
46. See text accompanying notes 3-5 supra.
47. May, Schizophrenia: Evaluation of Treatment Methods in 1
A. FREEDMAN, H. KAPLAN & B. SADOCK, COMPREHENSIVE TEXTBOOK OF Psy-
cHIATRY/II 955 (2d ed. 1975) [hereafter cited as CTP/II].
48. Nor do I intend to embroil myself in the vicious professional
squabbles that have characterized the assessment of the efficacy of psy-
chotherapy. I refer those interested in the subject to Malan, The Out-
come Problem in Psychotherapy Research, 29 ARCH. GEN. PSYCHIAT. 719
(1973).
49. To cite just a few problems, the effects of psychotherapy are
long term, and in any long relationship between psychotherapist and pa-
tient, effects of individual personalities are likely to be pronounced. In
addition, virtually all psychotherapy begins with a process of selection
by both the therapist and the patient, so that a random sampling is not
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state mental hospitals will not receive psychotherapy. The
economics of mental health will always commend pill-taking over
other forms of therapy in a public mental hospital. Administer-
ing drugs only takes a few minutes of professional time per
patient per day; psychotherapy, even if enough psychotherapists
were available, would take a few hours of professional time per
week. If right-to-treatment suits were to achieve their goal of
adequately staffed hospitals, it would cost so much per day that
any long-term stay-and all agree that the beneficial effects of
psychotherapy only occur after long-term treatment-would be
prohibitively expensive.50
A. A HYPoTIicAL SITUATION
Let us now consider a hypothetical person, diagnosed schizo-
phrenic, who stands before a court on a petition to commit him
for treatment. The person refuses to commit himself volun-
tarily and, further, refuses all forms of treatment. There is
no evidence of any significant likelihood that he will commit
any act dangerous to himself or others. The state's psychiatrists
say that they intend to treat him with antipsychotic drugs.
Using the analytical scheme set out above, the court must deter-
mine whether the treatment will benefit our patient and whether
the benefit is great enough, and the drug safe enough, to justify
confining him to receive the treatment.
really possible. Also, most psychotherapy patients are likely to be those
who can afford it and who do not feel stigmatized by it. In short, it
is almost impossible to separate the effects of the process from the effects
of the surroundings.
50. Thus when Professor Katz, in his thoughtful article, The Right
To Treatment-An Enchanting Legal Fiction?, 36 U. Cm. L. REv. 755
(1969), talks of coercing patients into accepting psychotherapy in state
mental hospitals, he reveals that, as a practicing psychoanalyst, he does
not realize what is available, or likely to be available, in public mental
hospitals. I might be as little worried about civil commitment as he is
if it involved only a short stay during which a psychotherapist tried to
talk a patient into talking and agreeing to stay. But this is not what
happens or what is going to happen. And since even the most ardent
psychotherapists are none too sanguine about the efficacy of psychother-
apy on the schizophrenics who comprise the bulk of American mental
hospital admissions, I'm not sure that a mental health system based on
psychotherapy would be a good thing. One careful study which com-
pared psychotherapy, drugs, and other treatments on newly admitted
schizophrenics concluded that
[fludging by our results, the value of individual psychotherapy
alone for the hospitalized schizophrenic patient has been greatly
exaggerated in some circles .... [It] is an expensive and in-
effective form of treatment that apparently adds little or noth-
ing to conservative milieu therapy.
P. MAY, TREATMENT OF SCHIZOPHRENIA 262 (1968) (emphasis deleted).
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B. WHAT ARE THE ANTIPSYCHOTIC DRUGS?
The most important and widely used of the antipsychotic
drugs is chlorpromazine, marketed by Smith, Kline and French
in this country under the trade name of Thorazine. 51 Although
this drug was originally synthesized as an antihistamine, a
French anesthesiologist discovered that it had a calming quality.
Noting this quality, two French psychiatrists tried the drug on
schizophrenic patients.52 Their positive results produced a "ther-
apeutic revolution" in the treatment of schizophrenia.
The therapeutic revolution initiated by chlorpromazine went far
beyond the mere pharmacological effects of the drug. Previ-
ously, many mental hospitals had been primarily custodial in
character. The fact that clinically significant therapeutic effects
could be produced by a drug created an atmosphere that empha-
sized positive treatment and led to the vigorous application of
milieu therapy, psychotherapy, group therapy, and occupational
therapy. The greater use of these social therapies was made
possible by the control, through medication, of the more disrup-
tive and destructive aspects of the patient's illness. The fate
of many patients who would otherwise have been permanent
residents of the mental hospital was profoundly altered. Some
were able to remain out of the hospital and function in the com-
munity. Other patients were discharged to nursing homes or
halfway houses. For those remaining in the mental hospital,
the hospital became a more humane place. And schizophrenic
patients who become ill today can often be treated effectively
by antipsychotic medication without hospitalization.53
Chemically, chlorpromazine is a phenothiazine, a word which
describes the nuclear structure of the molecule of a number of
related chemical compounds. 54 Some of these related compounds
also have antipsychotic properties. While some non-phenothi-
azines also have these qualities, it is the phenothiazines that are
most important among the antipsychotic drugs.
Among the phenothiazines, the literature is the most com-
plete regarding chlorpromazine. In order to keep this Article
51. See KLEIN & DAvis, supra note 34. These drugs are often
called the major tranquilizers, distinguishing them from the minor tran-
quilizers, like chlordiazepoxide (Librium), diazepam (Valium), and
meprobamate (Miltown). Most of those who deal with the antipsychotic
agents think that the term tranquilizer is a misnomer because the drugs
do more than simply tranquilize psychiatric patients. See, e.g., Mason-
Browne, Perphenazine-A Drug Modifying Consciousness, 114 AM. J.
PSYCHIAT. 173, 174 (1957).
52. See Delay & Deniker, Le Traitement des Psychoses par une
Methode Neurolytique Derivee de F'Hibernotherapie in CONGRES DES MED-
EcrIs A.LENISTEs NEuROLOGISTES DE FRANCE 497 (1952).
53. Davis & Cole, Antipsychotic Drugs in 2 CTP/II supra note 47,
at 1921-22 [hereafter cited as Davis & Cole].
54. See KLEIN & DAVIS, supra note 34, at 69-74.
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within manageable limits, I will primarily focus my attention on
that drug. In general it appears that chlorpromazine is a fair
example of the antipsychotic drugs to use for my purposes,5 5 and
my sampling of the literature of the antipsychotic drugs other
than chlorpromazine indicates that the criticism I direct towards
the chlorpromazine studies can be as easily directed towards
studies of other drugs.
C. FACTOR ONE: WHAT IS THE LIKELIHOOD THAT A SCHIZOPHRENIC
GIVEN ANTIPSYCHOTIC MEDICATION WILL IMPROVE?
As I have mentioned before, our standard for psychiatric
evidence ought to be high: certain methodological standards
ought to be met before we use a study as evidence of the efficacy
of a form of treatment. I do not pretend to have sifted all the
studies of chlorpromazine to come up with those with an ade-
quate research design; the published articles on chlorpromazine
by now number in the thousands.50 One of the most compre-
hensive drug textbooks, however, has done this sifting for me
and lists 61 articles 57 reporting research of an adequate design
in which chlorpromazine was compared with a placebo. The use
of a placebo for comparison is necessary because of the widely
recognized placebo effect: that receipt of a sugar pill and no more
will cause a significant number of people to recover from their
55. For example, Klein and Davis reviewed "selected studies
judged methodologically correct," KLEIN & DAVIS, supra note 34, at 55,
and found "no clearcut superiority for any one drug." Id. at 60. More-
over, a great deal of research since the early 1960's has been done with-
out placebos but using chlorpromazine for a comparison, on the assump-
tion that it was a drug of proven efficacy. See, e.g., Lasky, Klett, Caffey,
Bennett, Rosenblum & Hollister, Drug Treatment of Schizophrenic Pa-
tients, 23 Dis. NERv. Sys. 698 (1962). In such studies, while researchers
have found many drugs equal to chlorpromazine, they have thought none
clearly superior. See KLEIN & DAVIs, supra note 34, at 59 (chart of stud-
ies); Davis & Cole, supra note 53, at 1926 (more recent version of same
chart). Moreover, chlorpromazine appears to be by far the most popular
of the antipsychotic drugs. Klein and Davis report that a survey of
physicians showed that half of all phenothiazine prescriptions were for
chlorpromazine, KLEIN & DAvIs, supra. note 34, at 116.
56. Between 1952 and 1957 alone, 1067 studies of the therapeutic ef-
fects of chlorpromazine were published; from among these one critic
found only 37 that met minimum standards for research design and con-
trols. Heilizer, A Critical Review of Some Published Experiments with
Chlorpromazine in Schizophrenic, Neurotic and Normal Humans, 11 J.
CHRON. Dis. 102 (1960).
57. KLEIN & DAvIs, supra note 34, at 55, table 2. The list is only
current through 1969, but more recent updating of table 2 appeared in
Davis & Cole, supra note 53, at 1924; it revealed only four additional
studies in the intervening six years.
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illness, whether that illness be psychiatric or medical.58 If there
were no placebo comparison, one might think that a given drug
was effective when, in fact, the act of giving the pill alone would
have caused the cure or improvement, irrespective of the compo-
sition of the pill.
But from the studies reported in the textbook we must
remove the greater part, for they are not relevant to our hypo-
thetical schizophrenic. A few are irrelevant because they do not
deal solely with schizophrenics. 59 And almost four-fifths of the
58. KLEIN & DAVIS, supra note 34, at 28-29, 52; Bok, The Ethics of
Giving Placebos, 231 SCIENTIFIC AMERICAN, Nov. 1974, at 17; Porteus, Spe-
cific Behavior Changes Following Chlorpromazine, 21 J. CONSULT. PSY-
CHOL. 257, 259-60 (1957).
59. I have omitted from consideration eight studies with a mixed
population: Casey, Bennett, Lindley, Hollister, Gordon & Springer, Drug
Therapy in Schizophrenia: A Controlled Study of the Relative Effective-
ness of Chlorpromazine, Promazine, Phenobarbital, and Placebo, 2 ARCH.
GEN. PSYCHiAT. 210 (1960) (mixed acute and chronic schizophrenics: 81
percent chronic); Fromm & Forsberg, A Controlled Study on the Value
of Chlorpromazine in Allaying Anxiety, 17 DIs. NERv. Sys. 16 (1956) (21
psychiatric patients with anxiety as a prominent symptom; no indication
of number of schizophrenics among those); Gibbs, Wilkens & Lauter-
bach, A Controlled Clinical Psychiatric Study of Chloropromazine, 18 J.
CLIN. Exp. PSYCHOPATH. 269 (1957) (mixed diagnoses; only 10 of 39 ex-
perimental subjects diagnosed schizophrenic); Prange, Changing Psychia-
tric Treatment Patterns and Their Relationship to a Double-Blind Tran-
quilizer Study in a Teaching Hospital, 3 J. NEw DRUGS 75 (1963) (un-
specified number of psychotics mixed with nonpsychotics; no analysis
by diagnosis); Rathod & Rees, A Controlled Study of the Prognostic Sig-
nificance of Autonomic Responses in the Chloropromazine Treatment of
Disturbed Psychotic Patients, 104 J. MENT. SCI. 705 (1958) (mixed diag-
noses; only 11 of 27 schizophrenic); Seager, Chlorpromazine in the Treat-
ment of Elderly Psychotic Women, 1955 BRIT. MnED. J. 882 (48 el-
derly psychotic women of whom only 13 were schizophrenic; many in
hospital "for several years"); Winter & Frederickson, The Short-Term
Effects of Chlorpromazine on Psychiatric Patients, 20 J. CONSULT. Psy-
CHOL. 431 (1956) (59 patients of a variety of diagnostic categories);
Zeller, Graffagnino, Cullen & Rietman, Use of Chlorpromazine and
Reserpine in the Treatment of Emotional Disorders, 160 J.A.M.A. 179
(1956) (mixed diagnoses; 102 out of 176 subjects schizophrenic; length
of hospitalization unspecified). I have also omitted one study, Wilson,
McKay & Sandifer, A Double-Blind Trial to Investigate the Effects of
Thorazine (Largactil, Chlorpromazine), Compazine (Stemetil, Prochlor-
perazine) and Stelazine (Trifluoperazine) in Paranoid Schizophrenia, 107
J. MENT. SC. 90 (1961), whose drug trials were too short (two weeks
on each drug) and whose study population was too small (eight) to pro-
duce statistically significant results. See KLEIN & DAVIS, supra note 34,
at 424 (sample of 30-50 usually necessary to avoid "missing quite sizable
drug effects"); Overall, Hollister & Dalal, Psychiatric Drug Research:
Sample Size Requirements for One vs Two Raters, 16 ARCH. GEN. PSY-
cHiAT. 152 (1967) (sample size needs to be 40-60 to be sensitive even
to gross treatment effects).
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remaining studies were performed on schizophrenics who were
long-term residents of mental hospitals-quite a different type
from those outside mental hospitals, like the patient in our hypo-
thetical situation. Being in a hospital a long time "institution-
alizes" people6 ° and makes them much less able than their
counterparts outside institutions to take care of themselves.0 1
Studies showing an improvement in these patients may have no
relevance for a patient in our hypothetical situation.
The studies which are relevant to our hypothetical are those
concerning the newly admitted or "acute" schizophrenic (the
terms appear to be interchangeable), of which there are ten. (For
a listing of those ten studies, see Appendix.) Eliminating the
60. See text accompanying notes 139-43 infra.
61. Statistics tell the story: in California in the early sixties the
rate of release for patients continually hospitalized more than two years
was one to three percent per year. Adelson & Epstein, A Study of Pheno-
thiazines with Male and Female Chronically Ill Schizophrenic Patients,
134 J. NERv. & MENT. Dis. 543, 544 (1962). Long-term patients appear
not to have the capacity to adjust to the outside world. The chlorproma-
zine studies describe some of the long-term patients who were the sub-jects of the experiments as "deteriorated," Grygier & Waters, Chlorpro-
mazine Used with an Intensive Occupational Therapy Program: A Con-
trolled Study, 79 ARCH. NEuROL. & PSYCHIAT. 697 (1958), "intractable,"
Vaughan, Leiberman & Cook, Chlorpromazine in Psychiatry, 268 LANcET
1083 (1955), "institutionalized," Fleming, Spencer & Whitelaw, A Con-
trolled Comparative Investigation of the Effects of Promazine, Chlorpro-
mazine, and a Placebo in Chronic Psychosis, 105 J. MENT. Sci. 349 (1959);
or "deteriorated and apathetic," Shepherd & Watt, A Controlled Clinical
Study of Chlorpromazine and Reserpine in Chronic Schizophrenia, 19 J.
NEUROL., NEUROSURG. & PSYCHIAT. 232 (1956). The average patient in
these studies had been hospitalized from five to 18 years, and one patient
had spent 57 years in the mental hospital. The lowest average hospitali-
zation in the 37 studies dealing with chronic patients was 5.8 years, Dean
& Buker, Schizophrenia Treated With and Without Chlorpromazine, 55
RocKY MT. MED. J. 47 (April 1958); the highest was 18 years, Sommer-
ness, Lucero, Hamlon & Mahowald, Chlorpromazine: A Controlled
Study with Highly Disturbed Patients, 18 Dis. NEav. Sys. 16 (1957). The
patient with 57 years of hospitalization was reported in Porteus, supra
note 58. I have also eliminated five studies where patients were labelled
"chronic" but no information regarding length of hospitalization ap-
peared, because the term "chronic" seems to connote having been an in-
patient for a long period of time. But cf. Bennett & Kooi, Five Pheno-
thiazine Derivatives, 4 ARcH. GEN. PsYcnzAT. 413 (1961). Where the stud-
ies give the length of hospitalization, this assumption clearly appears to
be borne out. Some studies give a figure for duration of illness and
not length of hospitalization. Although one study specifically states that
duration of illness refers to time elapsed since the first onset of symp-
toms and not to the length of hospitalization, Roebuck, Chambers & Wil-
liams, An Evaluation of the Therapeutic Use of Triflupromazine in Men-
tal Disease, 129 J. NERV. & MENT. Dis. 184 (1959), I have assumed that




studies of chronic schizophrenics does not unfairly weigh the case
against chlorpromazine-quite the contrary. Psychiatrists gen-
erally expect that acute schizophrenics will respond better to
treatment than will chronic schizophrenics, 62 and this appears to
be true among the chlorpromazine studies.6 3
The studies cited in the Appendix, however, only begin to
tell the story. To impart a better notion of the significance of
this research, I will briefly analyze the research design and
results of the most important single study, the one done by the
National Institute of Mental Health Psychopharmacology Service
Center Collaborative Study Group, headed by Dr. Jonathan 0.
Cole 4 (hereafter referred to as Cole study). Even though this
study deals with drugs in addition to chlorpromazine, there are a
number of reasons why it is important. First, consider the ex-
cellence of its experimental design. Like all other studies cited,
the experiment was done double-blind using a placebo and
randomly assigning treatment to all newly admitted acute schizo-
phrenics. This ensured that there would be an unbiased selection
of patients in the study and in each group within the study.
Also, Cole's study used a large number of subjects, 344, to make
sure that the sample was unbiased. And it used patients at
nine different hospitals "representing an appropriately varied
range of psychiatric treatment settings,"65 in order to discover
62. See, e.g., KLEIN & DAVIS, supra note 34, at 54.
63. While Klein and Davis found that chlorpromazine was not sig-
nificantly better than placebo in 11 out of the 61 adequate studies they
surveyed, this happened in only one, Rosner, Levine, Hess & Kaye, A
Comparative Study of the Effect of Anxiety of Chlorpromazine, Reser-
pine, Phenobarbital, and a Placebo, 122 J. NERv. MENT. Dis. 505 (1955),
of the ten relevant studies listed in the Appendix. KLEIN & DAVIS, supra
note 34, at 55, table 2.
In the Rosner study, at no point by any test did either chlorproma-
zine or reserpine appear significantly better or worse than the inert
placebo. Klein and Davis's investigations indicate that the low dosage
of chlorpromazine (100 m.g./day) given in the Rosner study may account
for the apparent ineffectiveness of the drug. KLEIN & DAVIS, supra note
34, at 55. However, since I am presently only counting noses, this study
must be counted among those showing chlorpromazine ineffective.
64. National Institute of Mental Health-Psychopharmacology
Service Center Collaborative Study Group, Phenothiazine Treatment in
Acute Schizophrenia, 10 ARcH. GEN. PsycImAT. 246 (1964) [hereafter
cited as Cole].
65. Id. at 247. Two of the participating treatment settings were the
psychiatric units of general municipal hospitals in Washington, D.C. and
St. Louis. Four were state mental hospitals, three serving urban areas
and the fourth a rural area. One was a medium-sized hospital with al-
most no government support, and the last two were clinics, one in a




whether or not the effect of the drug depended on the environ-
ment in which the patient received it. Further, Cole's study
carefully described the patients included in the study;66 failure
to do so makes generalization "difficult and dangerous."67  The
psychiatrists thought most of the patients in this group to be
"markedly" or "severely" mentally ill at admission.6
The most difficult problem in the drug studies is measuring
the effect of psychiatric treatment. Cole's study used the most
common method for measuring outcome: a clinician's estimate
of whether or not the patient has improved. Psychiatrists in
the study rated patients at the end of the study on a seven-point
scale ranging from one (very much improved) to seven (very
much worse). Using this scale (see Figure 1), Cole discovered
a striking difference between the drug and placebo groups: while
over 20 percent of the placebo group remained unchanged and
another 20 percent got worse, no drug patient worsened and
only 5 percent remained the same; 95 percent got better-40
percent much improved and 30 percent very much improved.
Similar comparisons between the drug and placebo groups based
on the degree of illness after the treatment also showed a marked
drug effect (see Figure 2): almost half of the drug group was
66. The study included only those patients who had the following
characteristics:
1. Newly admitted to the hospital
2. Age-between 16 and 45
3. No significant hospitalization during the 12 months prior to
the current admission
4. No evidence of any of the following clinical disorders:
a. Childhood autism or childhood schizophrenia
b. Chronic or acute brain syndrome
c. Mental deficiency, with IQ below 70
d. Alcoholism as a significant feature of their clinical history(alcohol intake alone did not disqualify the patient)
e. Epilepsy
f. Drug addiction
5. Presence of two or more of the following symptoms or be-
haviors:
a. Thinking or speech disturbances
b. Catatonic motor behavior
c. Paranoid ideation
d. Hallucinations
e. Delusional thinking other than paranoid
f. Blunted or inappropriate emotion
g. Disturbance of social behavior and interpersonal relations
Id. at 247-48.
67. KLEIN & DAviS, supra note 34, at 423.
68. Cole, supra note 64, at 249-50. Psychiatrists rated the patients
at both the beginning and the end of the study on a seven-point scale
ranging from normal (one) to extremely mentally ill (seven). "Mark-
edly" and "severely" ill were, respectively, the fifth and sixth points on
the scale. See figure 2, page 1179 infra.
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rated only mildly ill or normal as compared to only 20 percent
of the placebo group, and half of the placebo group, as compared
with less than 20 percent of the drug group, was rated severely
or markedly ill. This is fairly impressive evidence 9 of the drugs'
effectiveness, especially when one recalls that the psychiatrists
did not know whether the patients they were rating were receiv-
ing the active drug or the placebo. 7t The other studies cited
69. The statistics become even more impressive if we include in the
final results the patients who were dropped from the research program
as "treatment failures"-those whose symptoms so increased that Cole's
group felt that retaining them in the research population would do them
psychiatric injury. Forty-three subjects dropped out of the study under
these circumstances; 36 of them were receiving placebo. Cole, supra note
64, at 248. Since these patients were rated by the psychiatrists as very
much worse, our statistics on improvement show that among the drug
patients, 3 percent were very much worse, 5 percent had no change, and
92 percent were improved; but that among the placebo patients 33 per-
cent were very much worse, about 15 percent were minimally to much
worse, 15 percent were unchanged, and the remaining 37 percent were
improved. In sum, almost half the placebo patients got worse, but over
90 percent of the drug patients got better. Treating these dropouts as
very much worse was suggested to me by Dr. John Davis, and this seems
reasonable. He felt, from his personal knowledge of some of the re-
searchers involved, that this standard was the one they had used for
dropping people from the study. At the very least, they were probably
rating them as either very much worse or worse, which would explain
why only about one percent of the whole study population was rated
in those two groups, with none at all rated very much worse. See Figure
1.
70. In some situations experimenters may not be fully in the dark
as to the identity of the drug patients. At least one recent study has
found that both experimenters and subjects could in fact differentiate
the allegedly identical placebo from the active drug on the basis of small
physical differences between the substances. The study suggested that
further precautions should be taken in future double-blind studies to in-
sure ignorance. Blumenthal, Burke & Shapiro, The Validity of "Identical
Matching Placebos", 31 ARCH. GEN. PsYcHIAT. 214 (1974).
Let us assume, however, that the placebo was in fact identical, for
there is an even more likely source of information that will lead to
breaking the blind: the common and annoying side effects of the anti-
psychotic drugs, see text accompanying notes 145-51 infra. In one study,
researchers felt that the inclusion of promazine, in which the occurrence
of side effects was highly variable, would confuse the treating psy-
chiatrists and insure that the blind was not broken by guesswork. See
Engelhardt & Freedman, Maintenance Drug Therapy: The Schizophrenic
Patient in the Community, 2 INT'L PSYCHIAT. CLINICS 933 (1965). In two
double-blind placebo studies raters were asked to guess which patients
were receiving the active drugs and which were receiving placebo; in
both cases, basing their judgment on drug side-effects, some raters were
able to pick out the drug patients from the placebo patients with a strik-
ing degree of accuracy. Grygier & Waters, supra note 61, at 700 (ward
sister picked five out of six drug patients on basis of photosensitivity);
Hall & Dunlap, A Study of Chlorpromazine: Methodology and Results
with Chronic Semi-Disturbed Schizcophrenics, 122 J. NERv. & MENT. Dis.
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in the Appendix generally agree with the Cole study, so that it is
fair to say that for the schizophrenic patient who receives drug
treatment there is a strong likelihood of improvement; if we use
Cole statistics we would predict that 95 percent of patients treated
with drugs will show an improvement that a psychiatrist would
notice.7 1
301 (1955) (basing their judgments on neurotoxicity, psychiatrist cor-
rectly guessed 56 out of 61 placebo patients and psychologist guessed 53
out of 63). Another study asserted, without quantifying the evidence
for its conclusion, that the
[s]o-called "double blind" method proved impossible at times
... as it was difficult to disguise the administration of chlorpro-
mazine from physicians and ward personnel because of the fre-
quent side effects of the drug and their absence with the
placebos.
Pleasure, Chlorpromazine (Thorazine) for Mental Illness in the Presence
of Pulmonary Tuberculosis, 30 PsycnrAT. Q. 23, 26 (1956).
The Cole study reveals a curious phenomenon which would undercut
the ability of the raters to pierce the blind via drug side effects. The
researchers discovered that a considerable number of placebo patients
developed some of the side effects associated with the active drug:
Treatment Given
Chlor-
Side Effect promazine Fluphenazine Thioridazine Placebo
Drowsiness 53.4% 36.3% 51.6% 9.5%
Restlessness 46.6 38.5 39.6 39.2
Constipation 33.0 27.5 20.9 12.2
Muscle Rigidity 12.5 24.2 4.4 8.1
Tremor of Hands, 5.7 12.1 13.2 5.4
Arms or Face
Cole, supra note 64, at 256.
There remains, however, a significant difference in the incidence of
side-effects between the drug and placebo groups. This difference, com-
bined with the intuitive notion shared by many psychiatrists that the
effective dosage-level of a drug is reached only when side effects appear,
may well have an influence on the outcome of studies.
71. These studies tend to establish a kind of validity for the diag-
nosis of schizophrenia. Ennis and Litwack have pointed out that the re-
liability of psychiatric diagnoses is low. The chances of two diagnosti-
cians agreeing on a diagnosis is fairly small, happening "somewhere in
the neighborhood of 40 percent" of the time. Ennis & Litwack, supra
note 31, at 702. There is some evidence that the restricted definition
of schizophrenia used by psychiatric researchers produces a greater relia-
bility of diagnosis than the experimental results that Ennis and Litwack
cited would indicate. For example, Kety reported a 67 percent correla-
tion on the diagnosis of definite schizophrenia between pairs of diagnosti-
cians who evaluated patients from records of interviews in a series of
studies concerning the genetics of schizophrenia. Kety, From Ration-
alization to Reason, 131 AM. J. PsYcHIAT. 957, 960 (1974). This figure
is quite a bit higher than that reported by Ennis and Litwack. It is,
of course, significant that the three raters in Kety's study had worked
a long time in psychiatric research and had "previously discussed and
reached some agreement on the criteria for a diagnosis of the three types
of definite schizophrenia" with which the study was concerned. Id. at
960.
The Kety study does, however, show something else of significance.
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The researchers reviewed the records of 365 persons; in 324 of those cases
all raters agreed that there were no signs of schizophrenia; in the 24
cases where at least one rater diagnosed chronic or definite schizophrenia
the other two raters saw signs of schizophrenia in all but one case. Thus
it would appear that the diagnosis of no schizophrenic symptions is much
more reliable than a diagnosis of definite or indefinite schizophrenia or
of schizoid personality. To phrase the point somewhat differently, this
study shows a high degree of correlation among raters about the symp-
toms of schizophrenia, but little correlation about the implications of
those symptoms. Letter, with enclosure, from Seymour S. Kety to Eu-
gene Z. DuBose, Jr., (Oct. 20, 1975) (on file at MINNESOTA LAW REVIEW).
But even if the diagnoses are no more reliable than Ennis and Lit-
wack report, the striking statistics on improvement do tell us something
quite valuable: drugs will reduce the prominence of whatever it is that
leads a psychiatrist to label someone schizophrenic. A diagnosis of
schizophrenia implies a responsiveness to treatment by antipsychotic
drugs.
There are three major ways in which medical science has tradition-
ally classified disorders: by symptom pattern, by prognosis, and by re-
sponse to treatment. See Falek & Moser, Classification in Schizophrenia,
32 ARcHmVs GEN. PSYCHAT. 59 (1975). Virtually all diagnosis in psy-
chiatry has been of the first variety: the illness is defined by the symp-
toms, and the symptoms are present patterns of behavior, often verbal
behavior. This type of nosology is disturbing to many since it only tells
us what the patient is doing now, nothing about either what he will do
in the future or how his behavior will change in response to treatment.
These latter questions are the essential questions in a system of legally
enforced, involuntary treatment. Thus, from the lawyer's point of view,
psychiatric diagnosis is only significant to the extent that it tells us some-
thing significant about prognosis or treatment response, and the assertion
in text that a diagnosis of schizophrenia strongly implies something
about treatment response is an extremely important advance on prior
learning.
In a way, the purpose of this Article is to examine the validity of
the psychiatric diagnosis of schizophrenia with regard to prognosis and
treatment response, and my formulation of the essential legal issues is
in many respects simply a reformulation of a long-standing psychiatric
debate about nosology. In part this is due to my decision to approach
the treatment issue from the perspective of a specific diagnostic category.
Had I chosen to define my issue in terms of the effect of psychiatric
treatment on a specific form of behavior-say, for example, violent as-
saults-this would not have been necessary. The strictures imposed by
the available information, however, compelled me to approach the ques-
tion as I have: there is virtually no research that is not couched in terms
of psychiatric diagnosis and that does not measure effect in terms of de-
gree of illness. The effect of treatment on a specific behavior pattern
is not a question, apparently, that interests psychiatrists. To them, the
question of whether the antipsychotic drugs "cure" schizophrenia is of
much greater import. To a great extent this orientation is, I think, due
to the fact that psychiatrists are medical doctors, whose previous training
has continually focused on the discovery and cure of illnesses. If, for
example, most psychiatrists were lawyers, the research would, I'm sure,
answer more lawyers' questions. But the research does not answer those
questions directly, and the questions that it does answer compel the
shape of this Article.
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D. FACTOR Two: WHAT IS THE SCOPE OF THE IMPROVEMENT?
1. The Meaning of Psychiatrists' Ratings of Improvement
Vastly more important than the likelihood of improvement
is what "improvement" means, a question that is very difficult
to answer from the chlorpromazine studies. Are we dealing with
someone who before treatment could not support or feed him-
self, but who can now care for himself in every way, or with
someone formerly a little odd (or maybe a lot) whom treatment
has made less odd (or much less)? Answering these questions
is not easy because the efficacy studies presume that everyone
knows what schizophrenia is and what clinical improvement is.




Doctor's pre- and post-treatment global ratings of mental
illness.
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can Medical Association, Reproduced by permission.
schizophrenic7 2 or whether he is improved 73 belie this assump-
72. See Ennis & Litwack, supra note 31, at 701-08.
73. Data concerning the concurrence of raters appears in very few
of the studies because the results are based either on one rater's opinion,
see, e.g., Reardon & Abrams, Acute Paranoid Schizophrenia (Treatment
with Chlorpromazine, Trifluoperazine and Placebo), 27 Dis. NER. Sys. 265
(1966); Rosner, Levine, Hess & Kaye, supra note 63, or on a consensus
of the staff, see, e.g., Fromm & Forsberg, supra note 59. Occasionally,
however, some of the variation does surface. In one study, whose results
rested on the evaluations of ten schizophrenics by two psychiatrists, the
two differed as to the degree of improvement in at least 50 percent of
the cases. Gibbs, Wilkens & Lauterbach, supra note 59. The percentage
may have been even higher but the method of reporting does not allow
the reader to verify greater discrepancies. In another study, a psychia-
trist and a psychologist each rated schizophrenic patients in a double-
blind placebo study. They differed as to degree of improvement in 38
percent of the placebo patients and in 50 percent of the drug patients.
Hall & Dunlap, supra note 70, at 305.
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tion, but there seems to be very little interest among psychia-
trists in making diagnosis more precise, or in developing accurate
tools for measuring behavioral changes. There is little research
carefully analyzing, in objective terms, either what a diagnosis
of schizophrenia indicates about a person or what kinds of
changes a judgment of improvement implies. That being the
case, we must approach these questions somewhat indirectly.
If we assume that the judgment that a schizophrenic has im-
proved means a reduction in the symptoms of schizophrenia, then
by ascertaining those symptoms we should be able to get some
idea of what it is that the drugs affect. There are, however,
substantial risks in this procedure. In the first place, the diag-
nosis of schizophrenia may vary idiosyncratically from diagnos-
tician to diagnostician, perhaps so much that the list of classic
symptoms tells us very little about what any given diagnosis of
schizophrenia reflects. The variation among diagnosticians that
Ennis and Litwack report may indicate precisely this phenome-
non.7 4 Similarly, the judgment that someone has improved psy-
chiatrically may tell us more about the psychiatrist than it does
about the patient. It may, for example, only indicate that the
psychiatrist has befriended the patient, or that the psychiatrist
has become more accustomed to the patient's behavior. For the
moment, though, in order to learn what psychiatrists think anti-
psychotic drug treatment of schizophrenics achieves, I will lay
these concerns aside.
The official definition of schizophrenia, promulgated by the
American Psychiatric Association is not particularly helpful. 75
It speaks generally of "characteristic disturbances of thinking,
74. See Ennis & Litwack, supra note 31, at 701-08; note 71 supra.
75. The American Psychiatric Association presents the following
definition of schizophrenia:
This large category includes a group of disorders manifested by
characteristic disturbances of thinking, mood and behavior. Dis-
turbances in thinking are marked by alterations of concept
formation which may lead to mis-interpretation of reality and
sometimes to delusions and hallucinations, which frequently ap-
pear psychologically self-protective. Corollary mood changes
include ambivalent, constricted and inappropriate emotional re-
sponsiveness and loss of empathy with others. Behavior may
be withdrawn, regressive and bizarre. The schizophrenics, in
which the mental status is attributable primarily to a thought
disorder, are to be distinguished from the major affective disor-
ders which are dominated by a mood disorder. The paranoid
states are distinguished from schizophrenia by the narrowness
of their distortions of reality and by the absence of other psycho-
tic symptoms.
AMERicAx PsYcIATRIc ASSOCIATION, DIAGNOSTIC AND STATISTICAL MANUAL
OF MENTAL DISORDERS (2d ed. 1968).
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mood and behavior," and the elaboration of these terms is just as
imprecise: disturbances in thinking "are marked by alterations
of concept formation;" mood changes "include ambivalent, con-
stricted and inappropriate emotional responsiveness and loss of
empathy with others;" and characteristic behavior may be "with-
drawn, regressive and bizarre." Obviously these protean terms
could comprehend anybody from Walter Mitty to Attila the
Hun.
The Cole study gives a slightly more concrete description.
Unlike other studies, it tabulated the frequency with which
symptoms occurred in the incoming population of acute schizo-










Generalized motor inhibition 18
Since a large number of clinicians, in nine different settings,
diagnosed these patients, it is fair to say that the listed symptoms
are an average cross-section of those that one would expect to
find in a randomly selected, nonhospitalized, acute schizophrenic
population. There is some evidence that a similar group of schi-
zophrenics from countries other than the United States would
demonstrate similar characteristics.7 7
76. This table was taken from Cole, supra note 64, at 249, table 5.
The article stated that the tabulation reflected only those symptoms
manifested "to a moderate or marked degree." Id.
77. Since 1965 the World Health Organization has been sponsoring
the International Pilot Study of Schizophrenia, a multinational epidem-
iological examination of schizophrenia. WORLD HEALTH ORGANIZATION, 1
REPORT OF THE INTERNATIONAL PILOT STUDY OF SCHIZOPHRENIA 3-4 (1973)
[hereafter cited as IPSS STUDY]. This study eliminated, as I have in
this article, long-term schizophrenic patients: it excluded all patients
with symptoms continually present for more than three years and those
who had been inpatients for more than two of the past five years. Id.
at 9. During the research period, April 1, 1968 to April 1, 1969, the nine
field reporting centers, in Aarhus, Agra, Cali, Ibadon, London, Moscow,
Taipei, Washington and Prague, reported 811 cases of schizophrenia and
tabulated symptoms for all patients. Differences in phrasing make it
unclear whether some of the symptoms that appear in the Cole study
are employed in the IPSS figures, but some of the IPSS statistics are
strikingly similar to the Cole statistics: lack of insight (=unrealistic
thinking?), 84.1 percent; suspiciousness, 60.2 percent; unwillingness to
cooperate (=social withdrawal?), 57.5 percent; auditory hallucinations,
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While this list of symptoms still does not provide a very con-
crete picture of the schizophrenics in the Cole study, it does tell
us that when psychiatrists diagnose someone as mentally ill-
schizophrenic, in particular-they are primarily concerned with
intellectual behavior. At least seven of the ten most com-
mon symptoms in the Cole study concern only the patient's
thoughts. Putting aside the fact that the information about in-
tellectual disorganization comes mostly from interviews between
the patient and the psychiatrist in the psychiatrist's office and
may not be reliable,7 8 can we justify forcing drug treatment on
a person solely to change the working of his mind?
To the extent that the administration of psychoactive drugs
achieves an entirely internal, intellectual change, to ignore a
refusal of treatment seems to me to border on the constitution-
ally impermissible. Although I have constructed a balancing
theorum to assess the permissibility of involuntary treatment
with antipsychotic drugs, that theorum rests on the implicit
proposition that treatment does more than alter ideas and per-
ceptions. Absent that something more, balancing is irrelevant
because we find ourselves in the realm of constitutional abso-
lutes. Even if we accept the position that r have rejected, that
the doctrine of substantive due process requires only "plausible
42.3 percent. Id. at 182, chart 10.15. This may prove nothing conclusive,
since diagnoses may vary radically from nation to nation. See, e.g., J.
COOPER, R. KENDALL, B. GURLAND, L. SHARPE, J. COPELAND, & R. SIMON,
PsYcHIATRIC DIAGNOSES IN NEW YORK AND LONDON (1972). But it may
indicate a difference in either incidence or recording of given symptoms.
In the IPSS study it is noteworthy that the frequency of the four symp-
toms I have listed above varied widely from center to center (ranges:
lack of insight 48.5 to 96.5 percent; suspiciousness 41.6 to 81.4 percent;
unwillingness to cooperate 30 to 76.3 percent; auditory hallucination 24
to 56.4 percent). And in the case of two of those symptoms the sole
American center, Washington, D.C., was at the low extreme (lack of
insight in only 48.5 percent of schizophrenic patients; auditory hallu-
cinations in 24.7 percent). IPSS STUDY, supra at 182, chart 19.15. It is
probably a mistake to expect a uniform international profile of symptoms
for schizophrenia-or even, perhaps, a uniform profile from one ward of
a hospital to another. See Pasamanick, Dinitz & Lefton, Psychiatric
Orientation and its Relation to Diagnosis and Treatment in a Mental
Hospital, 116 AM. J. PSYCHIAT. 127 (1959) (three ward administrators in
same hospital diagnose from 22.1 to 66.7 percent of their patients as
schizophrenic).
78. KLEIN & DAVIs, supra note 34, at 424, state:
Most [clinical] evaluations are made in an office-interview set-
ting. Often only minimal information is obtainable from the
patient. Patients are frequently at their best in the well struc-
tured office situation, whereas on the ward or at home their be-
havior might be radically different.
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arguments"79 in support of a state interest justifying the
interference with individual liberty, those arguments are hard
to come by in this area. Here there is no significant danger
in failing to treat the illness. How does it bother my neigh-
bor that I am suspicious or believe I hear voices? I may
annoy him with those ideas, but, as the Donaldson court put
it, "[m]ere public intolerance or animosity cannot constitu-
tionally justify the deprivation of a person's physical liberty."80
Perhaps having and expressing these ideas makes life difficult
for me, because my fellow men, who think me weird, are less
courteous, thoughtful or obliging than they might be. Life in
an institution, where those around me either understand or share
my weirdness and where I am relieved of the ordinary tasks of
daily life, might be easier. But the Donaldson dicta addressed
this point too: "the mere presence of mental illness does not dis-
qualify a person from preferring his home to the comforts of
an institution" 8' and expressed doubt that the institutional
ambience is an improvement anyway: "incarceration is rarely if
ever a necessary condition for raising the living standards of
those capable of surviving safely in freedom, on their own or
with the help of family or friends. '82 While the court's decision
rejected these alleged state interests in involuntary confine-
ment as inadequate only in the context of the state's failure to
treat during confinement, it seems logical to extrapolate from
the court's opinion that treatment which promoted only those
interests would also be constitutionally inadequate to justify con-
finement.
Furthermore, to justify a confinement on the basis of a purely
psychodynamic "benefit" to a patient may invade a constitution-
ally protected zone of privacy. Mr. Justice Brandeis, in a dissent
79. Tribe, supra note 20, at 18.
80. 422 U.S. at 575. This phrase echoed similar language in Coates
v. Cincinnati, 402 U.S. 611 (1971), also written by Mr. Justice Stewart,
which held unconstitutionally vague a statute forbidding an assemblage
of three or more people "in a manner annoying to persons passing by."
To the same effect is Mr. Justice Douglas's opinion in Papachristou v.
Jacksonville, 405 U.S. 156 (1972), which held unconstitutional a statute
making criminals of, among others, rogues, vagabonds, "common night
walkers" and "common railers and brawlers." But the Court based both
these decisions on the vagueness of the phrasing, on the failure of the
statutes to give fair warning to those who might run afoul of them.
Donaldson for the first time made explicit the substantive due process
notion that was implicit in these decisions: that incarcerating annoying
people solely because they are annoying is constitutionally impermissible.
81. 422 U.S. at 575.
82. Id.
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which has weathered the years better than the opinion with
which it differed, felt that the makers of the Constitution "sought
to protect Americans in their beliefs, their thoughts, their emo-
tions and their sensations. They conferred, as against the gov-
ernment, the right to be let alone-the most comprehensive of
rights most valued by civilized men." 3 This notion has no ex-
plicit source in any language of the Constitution,8 4 but seems
implicit in our constitutional system. It is only within the past
fifteen years, however, that the Supreme Court has begun to
give content to Brandeis's noble sentiments.8 5
For purposes of the problem we have before us now, the most
important privacy case is Stanley v. Georgia.88 In arguing for
affirmance of Mr. Stanley's conviction for possession of porno-
graphic movies in his home, the state of Georgia asked whether,
since "the State can protect the body of a citizen, may it not
... protect his mind?"87 The Supreme Court answered in the
negative, with reasoning akin to that of Mr. Justice Brandeis.
In the Court's view, the only possible explanation for Georgia's
action was its desire to control Mr. Stanley's "intellectual and
emotional needs."8 8 And this the Court found to be an imper-
missible state purpose; the state "cannot constitutionally premise
legislation on the desirability of controlling a person's private
thoughts."8' 9 Thus, although Stanley rested in part on the first
amendment,9 0 the Court's conclusion that the state purpose was
per se impermissible suggests partial reliance on a theory of sub-
stantive due process.
The step from Stanley to civil commitment is, in our case,
not a difficult one.9 1 Georgia wanted to remove a certain kind
83. Olmstead v. United States, 277 U.S. 438, 478 (1928).
84. Aware of this, Mr. Justice Holmes observed, as he concurred
with Brandeis, that "[cJourts are apt to err by sticking too closely to
the words of a law where those words import a policy that goes beyond
them." Id. at 469.
85. See, e.g., Roe v. Wade, 410 U.S. 113 (1973); Eisenstadt v. Baird,
405 U.S. 438 (1972); Griswold v. Connecticut, 381 U.S. 479 (1965).
86. 394 U.S. 557 (1969).
87. Id. at 560.
88. Id. at 565.
89. Id. at 566.
90. It is not wholly beyond reason to approach the case of our hypo-
thetical patient in first amendment terms when the change the state is
seeking is only to change his thoughts. Since the thoughts are only man-
ifested in speech, the state is confining and treating in order to change
the content of speech.
91. The Minnesota Supreme Court, expressing its hesitation to
define with any precision the right to privacy, did feel that "the core of
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of idea from Mr. Stanley's mind-ideas concretely represented
by the films that were the basis of the prosecution-in order
to protect him from himself, and perhaps to protect others from
his ideas, whether in their concrete or abstract form. For similar
reasons, we may wish to remove our hypothetical patient's
suspicions. In terms of what is important to one's personal integ-
rity, who is to say whether Mr. Stanley's pornography is any
more or less essential than our patient's suspicions? I have
occasionally heard psychiatrists assert that "there is no right to
be psychotic." It may be that not only is there such a right, but
that it is a constitutional one.
9 2
2. Other Devices to Measure Improvement: Clinical Rating
Scales
Although psychiatrists concern themselves almost exclu-
sively with verbal behavior and thought patterns, they are
convinced that the ideas there revealed reflect themselves in
patients' non-verbal behavior. To check this belief, I will look
the privacy decisions . . . is the concept of personal autonomy-the
notion that the Constitution reserves to the individual, free of govern-
mental intrusion, certain fundamental decisions about how he or she
will conduct his or her life," and used this yardstick to measure the
state's right to give involuntary treatment to a minor. Price v. Shep-
pard, 239 N.W.2d 905, 910 (Minn. 1976) (footnote omitted). One author,
more precipitate than Minnesota's judges, feels there is no problem at all
in jumping from Stanley to all manner of behavioral control, see Shapiro,
Legislating the Control of Behavior Control: Autonomy and the Coer-
sive Use of Organic Therapies, 47 S. CAL. L. REv. 237, 272-76 (1974), and
would create a "right to mentation" to protect all sorts of mental func-
tioning. I am not sure I fully understand how such a right works, or
what its limits are. I rather suspect, however, that Professor Shapiro
and I will not find ourselves much divergent in our attitudes towards
substantive problems.
92. One of the important problems with using the Stanley case is
its precedential weakness in light of more recent cases. United States
v. Reidel, 402 U.S. 351 (1971), decided two years after Stanley, held that
although Stanley permitted the possession of pornography, the conviction
of a distributor of pornography who mailed only to those who had ex-
pressed a desire to exercise their Stanley rights was nonetheless constitu-
tional, and United States v. Orito, 413 U.S. 139 (1973), decided four years
after Stanley, held that transporting one's own pornography from one
location to another may be criminally punished. Thus Stanley is, if not
doubtful, at least isolated. It may be that Stanley will become one of
those decisions like Shelley v. Kraemer, 334 U.S. 1 (1948), Reitman v.
Mulkey, 387 U.S. 369 (1967), or Robinson v. California, 370 U.S. 660
(1962), that remains a curious island in the stream of the law, never
overruled, never influencing the areas of law most closely adjacent to




at techniques other than clinical evaluation by psychiatrists for
measuring the effects of the antipsychotic drugs.9 3 Most of the
ten relevant studies (see Appendix) use some sort of stand-
ardized rating scale as a device to measure outcome. At first
glance one might think that these rather impressively formal-
ized devices will tell us something more about what improve-
ment means.9 4  However, there is virtually no evidence that
a given score on a device indicates anything other than that
the patient received that score. In fact, most of the "devices"
are nothing more than a series of questions about psychiatri-
cally interesting symptoms. An examination of one such device,
the Multidimensional Scale for Rating Psychiatric Patients
(MSRPP), 95 should suffice to make this point; it is particularly
relevant to our discussion since it was used in four of the ten
studies cited in the Appendix.
Developed in 1953 by Maurice Lorr, the MSRPP consists of 62
questions. Forty are answered by a psychiatrist on the basis of
93. One technique we need not examine is measurement of the ef-
fect of drugs on a patient's release from the hospital There is a belief
in the psychiatric community that when symptoms diminish, a patient
will be released from the hospital. Hence drugs are touted because they
'reduce the amount of time a patient has to stay in the hospital. This
drug effect is irrelevant to our considerations. A discovery that antipsy-
chotic drugs reduce the length of hospital stays would justify an argu-
ment that involuntary hospitalization for drug treatment will be short,
but not an argument that incarceration is justified in the first place.
94. In psychologist's terms, the question we are concerned with is
the "validity" of the test: what facts outside the device will be true
if the patient produces a certain score on the test? One occasionally
sees examples in the drug studies of tests that completely miss the mark.
In one study, for example, relatives were asked to rate the level of social
aggression over a period of months among schizophrenic outpatients; the
relatives' assessments were compared with seven clinical devices that
were thought to measure social aggression. There was no significant cor-
relation between the two indicators. Cohen, Freedman, Engelhardt &
Margolis, Family Interaction Patterns, Drug Treatment, and Change in
Social Aggression, 19 ARCH. GEN. PSYCHIAT. 50, 54-55 (1968). Thus what-
ever it was that the measuring devices thought was social aggression,
those who lived with the patients did not. And if those devices were used
to measure a patient's aggressiveness, they would be measuring a quan-
tity which had no relevance to the world outside of the hospital.
95. See Lorr, Multidimensional Scale for Rating Psychiatric Pa-
tients Hospital Form, VEmERAN'S ADM'N TECH. BULL. T.B. 10-507 (1953).
Developed from an earlier device, the MSRPP is no longer in use, having
been transmogrified into the Inpatient Multidimensional Psychiatric
Scale (IMPS). See M. LoaR & C. KLETT, INPATIENT MULTIDIMENSIONAL
PSYCHIATRIC SCALE (IMPS) (1966). Substantively the same as the
MSRPP, the IMPS was used in the Cole study; half of the studies
cited in the Appendix used the MSRPP or a variation of it.
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an interview with the patient; a nurse or psychiatric aide answers
the other 22 questions on the basis of ward behavior. The
questions themselves relate to conditions that most psychiatrists
view as symptoms of mental illness, 96 so it is not surprising that
in his original publication Lorr reported that a reduction in over-
all score on the MSRPP correlated with a reduction in number
and severity of symptoms in psychiatric patients.9 7 Indeed, in
96. For example, the following two questions could have been used,
one may imagine, to produce the conclusion of the Cole study that 60
percent of acute schizophrenics suffer from "excessive suspiciousness,"
see text accompanying note 76 supra:
33. Does he tend to suspect or to believe on slight evidence or
without good reason that some people are against him (per-
secuting, conspiring, cheating, depriving, punishing) in vari-
ous ways?
37. Does he tend to suspect or to believe on slight evidence or
without good reason that some people talk about, refer to,
or watch him?
Lorr, supra note 95, at 34-35. Both these questions can be answered in
four different ways, with the following numerical values given to the
answers:
1 No unjustified suspicions
2 Inclined to suspect
3 Inclined to believe
4 Has firm conviction
Id. It is in this manner that one arrives at numerical scores representing
the degree of illness.
97. Lorr, supra note 95, at 10. Lorr cited one other study where
the MSRPP was used to measure improvement and noted that the
MSRPP showed more improvement in lobotomized patients. That, how-
ever, does not prove it is a valid measure of improvement, but only that
lobotomized patients get higher scores.
I have located only one other piece of research attempting to validate
the MSRPP, and it deals with ward behavior ratings. See Ellsworth &
Clayton, Measurement of Improvement in Mental Illness, 23 J. CONSULT.
PSYCHOL. 15 (1959). Having dropped several MSRPP questions as being
too unreliable, Ellsworth and Clayton noted that the behavior ratings on
the nurse-completed portion of the MSRPP correlated with community
adjustment some months after release from the hospital. Community
adjustment, however, consisted of another scale, devised for the study.
Under this scale 25 psychiatric patients were rated in six areas of social
adjustment. Ellsworth and Clayton state that "[t]hese included occupa-
tional (or school) adjustment, management of funds, family adjustment,
other interpersonal relationships, recreational adjustment, and com-
munity adjustment." Id. at 19. No further analysis or discussion is
provided by the authors, however, as to what these six areas of "adjust-
ment" represent. Since Ellsworth and Clayton do not tell us what their
"adjustment" represents, we are left in the dark. This is particularly
distressing in view of the fact that whatever the community adjustment
scale did measure is precisely the kind of evidence we need to assess
accurately the value of drug treatment for schizophrenics. As it stands,
all we know is that if you get a good score on one scale, you will get a
good score on another scale.
This kind of approach is typical in the insular world of psychiatry.
19761 1187
MINNESOTA LAW REVIEW
large part the MSRPP is no more than a way of standardizing
the psychiatric interview.98 In a field where standardization is
the exception rather than the norm, this is a worthwhile
step.9 9 But it means that studies using the MSRPP and similar
devices to measure improvement from drug treatment are unable,
to the extent that they merely incorporate a standardized psy-
chiatric interview, to show improvement different in kind from
that shown in studies that measure improvement according to
psychiatric evaluations. They fail, that is, to demonstrate
changes in non-verbal and non-psychodynamic behavior and,
Tests which are really only groupings of symptoms with arbitrary nu-
merical values tacked on are used to prove that treatment is effective.
For the most part, all they prove is what the psychiatrist improvement
ratings prove: that a rater thinks someone has fewer or less severe
symptoms. Yet psychiatrists opine that "[t]he MSRPP has been well
validated .... ." Casey, Bennett, Lindley, Hollister, Gordon & Springer,
Drug Therapy in Schizophrenia, 2 ARCH. GEN. PSYCHIAT. 210, 217 (1960),
which reveals only how carelessly they have examined the literature.
98. Lorr has some rather odd ideas about what his tests prove. Us-
ing the IMPS, he noted that the answers to similar questions, like those
set forth in note 96 supra, tended to be similar. From correlations such
as this he deduced that he had discovered ten psychotic syndromes. See
Lorr, McNair, Klett & Lesky, Evidence of Ten Psychotic Syndromes, 26
J. CONSULT. PSYCHOL. 185 (1962). A critic noted that all he had really
proven was that if you ask a person similar questions you will probably
get similar answers. Eysenck, Psychoticism or Ten Psychotic Syn-
dromes? 27 J. CONSULT. PsycHoL. 179 (1963). But see Lorr, McNair,
Klett & Lesky, Canonical Variates and Second Order Factors: A Reply,
27 J. CONSULT. PSYCHOL. 180 (1963).
99. Lorr, supra note 95, at 9-10, reports a fairly high degree of
reliability among users of the scale, as did Kurland, The Comparative
Effectiveness of Six Phenothiazine Compounds, Phenobarbital and Inert
Placebo in the Treatment of Acutely Ill Patients: Global Measures of
Severity of Illness, 133 J. NERv. & MENT. Dis. 1, 4, but in neither case
did the study reveal its procedures. The one other study showing a
high degree of reliability among various individual users of the MSRPP
used standardized interview techniques and questions that the MSRPP
did not require or advise and, in addition, adopted "specific 'conventions'
... concerning those items which most frequently showed disagree-
ment in an attempt to reduce inter-rater variability." Stillson, Mason,
Gynther & Gertz, An Evaluation of the Comparability and Relia-
bility of Two Behavior Rating Scales for Mental Patients, 22 J. CONSULT.
PSYCHOL. 213, 214 (1958). One must assume that without these precau-
tions, all of which Lorr ignores, MSRPP scores would demonstrate a
much greater variation. One other study, which again does not mention
precautions against variations, shows a fairly high degree of agreement
where the raters consisted of teams that rated by consensus. Klett &
Lasky, Agreement Among Raters on the Multidimensional Scale for Rat-
ing Psychiatric Patients, 23 J. CONSULT. PsycHoL. 281 (1959). Psychia-
trists, in any case, have scrutinized the reliability of the MSRPP much
more than they have its validity.
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therefore, to avoid infringing a patient's constitutional right to
privacy as articulated by Stanley.
Although the greater part of the MSRPP consists of psy-
chiatric information garnered from psychiatric interviews, about
a third of the test consists of questions about the patient's ward
behavior to be answered by a psychiatric aide or nurse who
knows the patient. The test thus moves beyond mental and ver-
bal behavior to behavior which might be a legitimate concern of
the state. Unfortunately the vast majority of questions are about
behavior which is either relevant primarily to the smooth admin-
istration of the hospital 00 or of only slight interest to society at
large.101 In all, of the 22 questions on ward behavior only four
seem to reflect significant state concerns: whether the patient
works in the hospital, whether he destroys property, whether he
assaults others, and whether he swallows objects other than food.
The scores on these items will have only a small impact on the
overall score on the test. And while researchers may have data
concerning the effect of drug therapy upon these particular
responses, they have published none to date.102  On the whole,
100. There are questions about his eating habits (#41); sleeping
habits (#49); adaptability to the hospital routine (#48); amusements
(#57); personal hygiene (#53); daily routine (#50); and resistance to
the daily routine of the hospital (#55). Lorr, supra note 95, at 37-40.
Many of these questions reflect the fact that many of the patients rated
have been institutionalized for years.
101. There are a number of questions about talking: does he "swear,
curse, or use dirty language?" (#43); "talk to himself?" (#44); "talk
if spoken to?" (#52); "talk in a straightforward, sensible way?" (#54);
or "speak to others?" (#56). Lorr, supra note 95, at 37-39. There are
some about his level of activity: is he "restless?" (#42); does he
move faster or slower than average? (#45); is he lively or lethargic?
(#46). And some about his sociability: is he "irritable and grouchy?"
(#47); "does he like being with people?" (#58); and does he "tease,
pick on, brow-beat or bully others?" (#61). This concern with behavior
that the legal system would think trivial is typical of ward behavior
rating devices. See, e.g., Raskin & Clyde, Factors of Psychopathology in
the Ward Behavior of Acute Schizophrenics, 27 J. CONSULT. PSYCHOL.
420 (1963) (showing similar concerns in Ward Behavior Rating Scale).
102. For example, in the Kurland study all of the MSRPP scores
were available for the 187 patients in the study, but "[t] o avoid unwield-
iness, excessive length, and overcomplexity in presentation, the present
paper will be limited to reporting differences in efficacy of the drugs
as measured by the MSRPP total morbidity scores and by psychiatrists'
global evaluations of adjustive capacity." Kurland, supra note 99, at 6.
Even when more precise breakdowns of the MSRPP were published,
it was done by factors, that is, by groups of questions, and not by in-
dividual questions. Hence the question on assaults was weighed equally
with the questions on bullying (#61), irritability (#47), hostility
(#12), resistance (#55), and profanity (#43). Lorr, supra note 95, at
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efficacy studies using standardized devices have concentrated on
overall "sickness" as revealed by the total test score, not on
specific behaviors. 0 3 Thus we are left with almost no evidence
from controlled studies about the effect of drugs on legally sig-
nificant behavior. To give the studies their due, however, it
must be acknowledged that, since overall scores were clearly
15. Thus an "improvement" in this factor might represent fewer as-
saults, or less bullying, irritation, hostility, resistance or profanity, or
some combination of all six. Interestingly enough, Kurland's study
revealed no significant difference between drugs and inert placebo groups
with respect to this factor on the MSRPP or on similar devices. Indeed,
it was found that everyone, except those who received phenobarbital,
calmed down in the hospital; the phenobarbital patients became increas-
ingly hostile and beligerent. See Kurland, supra note 99, at 54. See also
Hogarty, Goldberg, Schooler & The Collaborative Study Group, Drug and
Sociotherapy in the Aftercare of Schizophrenic Patients: III, Adjust-
ment of Nonrelapsed Patients, 31 ARCH. GEN. PSYCHIAT. 609 (1974) [here-
after cited as Hogarty] (extensive post-hospital survey of drug effects;
all results in terms of factors in rating devices).
103. Occasionally studies deal with some other measuring devices,
but those studies show little drug effect. Changes in I.Q. over the period
of treatment, for example, seem unrelated to drug effect: the scores gen-
erally go up for both drug and placebo patients. See Abrams, Chlorpro-
mazine in the Treatment of Chronic Schizophrenia, 19 DIs. NERv. SYs.
20 (1958); Reardon & Abrams, Acute Paranoid Schizophrenia (Treat-
ment with Chlorpromazine, Trifluoperazine and Placebo), 27 Dis. NERV.
Sys. 265 (1966) (acute paranoid schizophrenics; on four of the subtests
of the Wechsler Adult Intelligence Scale, however, chlorpromazine, one
of the two active drugs in the experiment, did produce significantly
higher test scores than did placebo). Similarly, chlorpromazine seems
to have no effect on the ability of a patient to learn simple motor tasks.
Whitehead & Thune, The Effects of Chlorpromazine on Learnings in
Chronic Psychotics, 22 J. CONSULT. PSYCHOL. 379, 383 (1958) (chronic
psychotic males).
Although it did not happen in any of the ten relevant studies cited in
the Appendix, in some studies researchers have had to ignore findings
that chlorpromazine is ineffective in reaching their conclusion that it is
effective. See, e.g., Fox, Gobble, Clos & Denison, A Clinical Comparison
of Trifluperidol, Haloperidol and Chlorpromazine, 6 CuR. THER. RES. 409
(1964) (depending on which of three measuring devices one chose, chlor-
promazine was either the best or the worst drug in the study). See also
Gallant, Bishop, Timmens & Steele, A Controlled Evaluation of Triflu-
peridol, 5 CuR. TnER. RES. 463, 469 (1963) (concluding that Brief Psy-
chiatric Rating Scale, now one of the most popular measuring devices,
was an inadequate measure because, unlike other devices, it failed to
show an improvement on drugs).
As one might expect, research has shown that the interrelationships
between various measuring devices vary greatly; one study showed a
range from 0 (absolutely no relationship whatsoever) to 0.92 (almost
perfect one-to-one correlation. May & Tuma, Choice of Criteria for
the Assessment of Treatment Outcome, 2 J. PSYcmAT. RES. 199 (1964).
Hence to some extent the research conclusion about whether the
drug is effective is determined by what measuring device one selects.
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improved by drugs as compared to placebo, there is some possi-
bility that drugs do affect work, physical aggression, and self-
injurious behavior.
Even if ward behavior ratings clearly indicated specific im-
provement due to drug treatment, however, we would have to
be leery of concluding from those results that improvement in
the hospital correlates to improvement in the outside world. A
study by Ellsworth of inpatient schizophrenics,' 0 4 that collected
data from the hospital staff and the patients' families both during
and after hospitalization, rejected the hypothesis that a patient
who improves in the hospital will function better in the outside
world than one who does not. First, the study found almost no
correlation between staff and family ratings of patients at the
time of admission. The sole exception was that patients whose
families thought of them as showing good contact with reality,
generally acceptable behavior, and friendship skills, the staff
perceived as anxious. In short, people who got along well in the
world became upset when they went into the hospital. 0 5 Thus
while hospitals may cure symptoms such as anxiety, 0 6 they may
cause them first. And perhaps what drugs do in reducing those
symptoms is not so much cure the patient as help him get used to
the hospital107
Second, the researchers discovered that there was "very
little" 0 8 relationship between the staff's estimate of the patient's
condition at release and the family's perception three weeks after
release. On only two items was there any degree of cor-
relation. 0 9 On the whole, Ellsworth's team found that percep-
tions of the patient's behavior varied more with the situation
104. Ellsworth, Foster, Childers, Arthur & Kroeker, Hospital and
Community Adjustment as Perceived by Psychiatric Patients, Their
Families and Staff, 32 J. CONSULT. & CLIN. PSYCHOL.: MONOGRAPH SUPP.
1 (1968) [hereafter cited as Ellsworth).
105. As Ellsworth and his co-workers put it: "for some patients at
least, such problems as anxiety, confusion, and hostility may be, to a
large extent, hospital-induced phenomena." Id. at 31.
106. "Severe anxiety" was the second most common symptom among
patients in the Cole study. Cole, supra note 64, at 249 (occurring among
64 percent of patients). See text accompanying note 76 supra.
107. See text accompanying notes 139-43 infra.
108. Ellsworth, supra note 104, at 27.
109. One correlation was that those patients the hospital staff
thought "motivated" tended three weeks later to hold jobs and have sub-
stantial earnings. One might guess that the staff's judgment about moti-
vation was influenced by the patient's perceptions of whether he would
get a job when released. The other correlation was that those the staff
thought "friendly and trusting" were those the family said had friends.
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-where he was, who he was with, and what he was doing-
than with the patient. In other words, the underlying thesis
that the well-integrated person functions equally well and with
equal success in all circumstances proved false.
The observation that perceptions vary according to circum-
stances brings out another aspect of the problem of rating be-
havior and improvement. There are a number of different
people and institutions involved in every process of rating
behavior, and the interests of each rater may be quite differ-
ent.110 A patient's family may not desire the same tractable
behavior that the ward staff does, and an employer certainly will
want an employee more independent than could be tolerated
easily on a well-run psychiatric ward. But, nonetheless, it is the
opinion of the ward staff that determines what is perceived as
sick and what is perceived as healthy. In any event, the psy-
chiatric rating devices do not appreciably increase our knowledge
of the scope of the antipsychotic drug effect on schizophrenics.
None of the double-blind efficacy studies cited in the Appendix
provides significant evidence in that regard. Since some of the
devices include some quantification of behaviors of possible legal
significance, we might suspect that there is some effect on these
behaviors, but until these effects are more precisely analyzed,
we cannot be certain of this. Moreover, the Ellsworth study
should make us doubt that measurements taken on the ward will
correlate with behavior outside the hospital. To get an idea of
the scope of the drug effect, then, we have to look to research
evaluating behavior in terms more easily translatable to the legal
context.
3. Other Research on Scope of the Drug Effect
There are few off-ward studies of the effects of drug treat-
ment,"' and those which do exist are not all of adequate de-
sign; 1 2 however, they must suffice.
110. Erickson, Outcome Studies in Mental Hospitals: A Search for
Criteria, 39 J. CONSULT. & CLiN. PsYcHoL. 75, 85 (1972) ("There are as
many sets of criteria for success as there are interested parties in-
volved.").
111. Off-ward research by psychiatrists is rather unusual. Psychia-
trists are medical doctors and, as such, are creatures of the laboratories
and the wards; they do not know how to research in the field and, for
the most part, do not.
112. See Hogarty, Goldberg & The Collaborative Study Group, Drug
and Sociotherapy in the Aftercare of Schizophrenic Patients: One Year
Relapse Rates, 28 ARcH. GENr. PSYCHIAT. 54 (1973) [hereafter cited as
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Job performance: I have found two studies dealing with the
job performance of drug-treated schizophrenics. Both reach
somewhat equivocal results. One well-controlled study showed
that the job performance of outpatient schizophrenics with a poor
work history improved on drugs as compared to that of similar
patients receiving placebo, but that those with a good work
history regressed with drug treatment.11 3 Another employment
study, made on former psychiatric patients who were part of the
Cole study, found that hospitalization and treatment did not
return patients to their pre-hospitalization level of functioning:
fewer held steady jobs, more did not work, few were working at
jobs equivalent to their prior best jobs, and barely half were self
supporting.1 4 Whether these differences between job perform-
ance before and after hospitalization were due to the onset of
schizophrenia or to other effects of drugs-or of hospitalization,
since simply being in the hospital for an extended period of time
may cause one to lose his job-is not clear.1 5 Nonetheless, the
results of both studies make one question the assumption that
hospitalization and drug treatment will directly benefit a patient's
ability to support himself outside the hospital.
General social functioning: Psychiatrists often contend that
inability to function in society is one of the results of schizo-
phrenia. Exactly what they mean by inability to function is
difficult to determine. One well-controlled study with schizo-
phrenic outpatients, using a checklist of "15 items describing
clearly dysfunctional social behavior," found that drugs signifi-
cantly alleviated these behaviors." 6 Unfortunately, the study
The Collaborative Study Group] (reporting only two previous adequate
studies on the effects of drugs on formerly hospitalized schizophrenics).
113. Engelhardt & Freedman, supra note 70, at 951-52. Work adjust-
ment was measured by number of jobs held, days missed, amount of
time worked, and the like.
114. Hall, Smith & Shimkunas, Employment Problems of Schizo-
phrenic Patients, 123 Am. J. PSYCHAT. 536 (1966). See also Schooler,
Goldberg, Boothe & Cole, One Year After Discharge: Community Ad-
justment of Schizophrenic Patients, 123 AM. J. PsycHIAT. 986 (1967)
(dealing with same subjects as Hall-Smith-Shimkunas study).
115. The Hall-Smith-Shimkunas study, see note 114 supra, does not
note which of the patients received drugs and which received placebo
during the Cole study. It may be safe to assume that almost all the
patients received drugs. Seventy-eight percent of those who completed
the study received drugs, see Cole, supra note 64, at 248, and those still in
the hospital after the study were treated, most likely, with drugs. See
Schooler, Goldberg, Boothe & Cole, supra note 114, at 994 (1967). Still,
there must have been some who never received drugs, id. at 991, and it
would be interesting to know how they fared.
116. Englehardt & Freedman, supra note 70, at 950.
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did not mention what those behaviors were, so the legal system
cannot judge whether they were in fact "clearly dysfunctional.""7
Moreover, the improvement, which appeared after six months of
treatment, ceased later. And apparently the dysfunctional be-
havior of placebo patients also improved with time." 8
The Hogarty study," 9 which is probably the best and most
extensive of those dealing with the long-term social effects of
drug therapy on schizophrenics, also suffers, in the legal point
of view, from imprecision. This study followed over 100 former
patients for a two-year period. The researchers found some sig-
nificant differences between drug and placebo patients according
to a number of devices measuring social adjustment, but the
information does not indicate whether any of the differences are
legally significant. 20 There are, however, a few important
points to be drawn from the study. The great majority of impor-
tant changes in social behavior were due not to the drug alone,
but to a combination of drug and major role therapy ("a combina-
tion of intensive social casework and vocational rehabilitation
counseling").121 Moreover, almost no major changes occurred
117. The study did mention that
the most consistent and specific findings obtained were in the
area of social isolation and social aggression, particularly the
type of social aggression which the relative [of the patient who
was reporting the behavior] experienced as directly oppositional
to his wishes.
Id. at 951. The aggression which this passage speaks of, apparently an
inclination to object when a relative opposes him, should not, I think,
be termed "clearly dysfunctional." Certainly a patient who does not as-
sert himself is tractable, but asserting oneself has great social util-
ity. Again, the evidence here points to a drug effect similar to that
which I have hypothesized that the drug studies show: a more compliant
patient.
118. Id. at 952.
119. Hogarty, supra note 102. This study and its findings are not
completely relevant to our inquiry. The study dealt with patients who
had received chlorpromazine for two months after release from a hos-
pital. It was only after this initial period that the researchers randomly
assigned patients to either continued chlorpromazine or a placebo. Hence,
as we are looking for comparisons between conditions before and after
hospitalization in order to determine what the overall benefits of drugs
are, this study is of limited value. On the other hand, insofar as it deals
with the long-term social benefits of receiving drugs as compared with
placebo, it is important because, within its limits, it does tell us that
the drug alone does not seem to affect social functioning in a major way.
120. Curiously, the differences between the groups related only to
specific factors; there were no differences between any groups on the
basis of total scores on the devices, id. at 612, no overall differences in
degree of illness between drug and placebo patients living in the commu-
mity, that is.
121. Hogarty, Goldberg, Schooler, Ulrich & The Collaborative Study
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before 18 months of treatment. Thus, where treatment consists
of drugs alone, without long-term counseling of outpatients, as is
the case in most public mental health systems, one can not expect
significant improvement in general social functioning.
The rate of hospitalization or rehospitalization among schizo-
phrenics treated with drugs versus those treated with placebo
has received more attention from researchers than have more
specific elements of social adjustment. This is significant to our
discussion because in discussing the social disabilities that ac-
company schizophrenia psychiatrists cite, as evidence of those
disabilities, statistics gathered over the past 40 years that show
that a high percentage of schizophrenics remain hospitalized for
long periods of time.
1 22
The more carefully designed studies do show that continuing
drug treatment reduces the rate of hospitalization among schizo-
phrenics. Pasamanick's study, for instance, dealt with newly
admitted acute schizophrenics who were randomly assigned to
home care with antipsychotic drugs or placebo. After thirty
months, although some in each group were hospitalized, the study
concluded that over twice as many drug patients stayed out of
the hospital as did placebo patients.' 23 Hogarty and his asso-
ciates ran a two-year controlled study with formerly hospitalized
schizophrenics that reached the same result.1 24 And a third study
Group, Drug and Sociotherapy in the Aftercare of Schizophrenic Patients:
II, Two-Year Relapse Rates, 31 ARCH. GEN. PsYcHIAT. 603 (1974) [here-
after cited as Hogarty & The Collaborative Study Group].
122. See Lehmann, Schizophrenia: Clinical Features, in CTP/II,
supra note 47, at 919-21. As of a few years ago, the average schizo-
phrenic in a mental hospital had been there about ten years. M. KRAMER,
E. POLLACK, R. REDICK & B. LOCKE, MENTAL DIsORDERS/SUIcIDE at 51,
figure 3.6 (1972).
123. B. PASAMANicK, F. SCARPITTI & S. DINiTz, SCHIZOPHRENICS IN THE
COMMUNITY (1967) [hereafter cited as PASAMANICK]. The study
found that 77 percent of the drug patients remained out of the hospital,
while only 34 percent of the placebo patients did. Id. at 250. After five
years, when the initial program of home care had ceased, the three
groups were not significantly different in any respect. A. DAvis, S. DIN-
rrz & B. PASAMANICK, SCHIZOPHRENICS IN THE NEW CUSTODIAL COMMU-
NITY: FIVE YEARS AFTER THE EXPERIMENT (1974). The differences, then,
were not permanent.
124. Hogarty & The Collaborative Study Group, supra note 121. In
this study, patients at three aftercare clinics, after a two-month period
during which all received antipsychotic drugs, were randomly assigned
to one of four groups: drug, drug plus major role therapy, placebo, and
placebo plus major role therapy. Defining relapse as "clinical deteriora-
tion of such magnitude that hospitalization seemed imminent," The
Collaborative Study Group, supra note 112, at 55, they discovered that
over two years, 80 percent of the placebo patients relapsed while only 48
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referred to as the Downstate study, dealing with schizophrenic
outpatients only some of whom had formerly been hospitalized,
showed similar results over a four-year period.125 All three
studies show that while drugs reduce hospitalization, they do not
eliminate it.
On the other hand, an as-yet-unpublished study conducted
at Agnews State Hospital in San Jose, California, reached quite
a different result. It appears to show that drugs increase the
likelihood of hospitalization. The researchers chronicled 127
young male inpatients diagnosed as acute schizophrenic. 1 2  Pre-
dictably, those receiving the active drug improved significantly
more between admission and discharge than did those on placebo,
but between discharge and follow-up (as much as 36 months
later) 57 percent of those who received the active drug improved
while 79 percent of those who had received the placebo improved.
The conclusion was that "[i]n the long run, most patients not
given phenothiazine medication do better clinically.' ' 1 27 Similarly,
percent of the drug patients did. Three-quarters of those who relapsed
were in fact hospitalized. Thus, although drugs may reduce hospitaliza-
tion and rehospitalization, we should not necessarily conclude that this
implies a reduction of any socially significant misbehavior.
There is another difficulty with some of these studies. Even if we
accept Hogarty's and Pasamanick's conclusions that drugs prevent hos-
pitalization, compare text accompanying notes 126-31 infra, we could
not apply their research to the average schizophrenic in the mental
health system, because both of their studies used sampling procedures
which insured elimination of average schizophrenics. Hogarty rejected
alcoholics and transients from his study; this eliminated one-half of the
male schizophrenics in the population he was drawing from. The Col-
laborativf Study Group, supra note 112, at 55-56. And Pasamanick elim-
inated 70 percent of all schizophrenics who entered the local hospital
on the basis of the staff psychiatrist's judgment that they were simply
not "acceptable" for the program. PASAMANICK, supra note 123, at 40,
81 n.l. In short, the patient population on whom these careful studies
were performed is significantly unlike the patient population that comes
in the door of a mental hospital and hence is significantly unlike our
hypothetical patient.
125. See Engelhardt, Rosen, Freedman & Margolis, Phenothiazines
in Prevention of Psychiatric Hospitalization, 16 ARcH. GEN. PSYCHIAT. 98
(1967) [hereafter cited as Downstate study]. They found that over a
four-year period, only 20 percent of the drug patients were hospitalized
while 30 percent of the placebo patients were. Id. at 100. This lower
rate is probably due to the fact that not all of their patients had been
previously hospitalized.
126. Rappaport, Hopkins, Hall, Belleza & Silverman, Schizophren-
ics for whom Phenothiazines May Be Contra-indicated or Unnecessary
(unpublished study on file at MINNESOTA LAW REVIW). The study is
silent as to whether it was double-blind and so we must assume it was
not. This factor of course undermines the study's conclusions.
127. Id. at 9.
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while only 8 percent of those who had inactive medication either
in the hospital or afterwards had been rehospitalized, 59 percent
of those who had taken phenothiazines, either during hospitali-
zation or afterwards, had gone back into the hospital. It almost
seems that in this study the medication fostered hospital depen-
dence rather than independence. 12
At least one other study suggests that drugs are not a factor
in the ability of schizophrenics to survive outside a hospital.
A recent article by Bockoven and Solomon compared two five-
year follow-up studies of mental patients at two separate but
similar clinics in the Boston area,1 29 only one of which made
"extensive use" of antipsychotic drugs. Surprisingly, schizo-
phrenics in each group fared about equally well after five
years;130 drug treatment appears to have had no discernible effect
on the ability of these schizophrenics to live outside a hospital.1' 1
128. The Downstate study noted a similar effect among some schizo-
phrenic outpatients. Rosen, Engelhardt, Freedman, Margolis & Klein,
The Hospitalization Proneness Scale as a Predictor of Response to Pheno-
thiazine Treatment, 152 J. NERv. & MENT. Dis. 405 (1971). They found
that among those schizophrenics who tend not to go into hospitals, the
use of antipsychotic drugs will increase the likelihood of hospitalization.
One other study also discovered that patients receiving placebo during
hospitalization were significantly less likely to be hospitalized again
within a year after discharge than those who received an active drug.
Schooler, Goldberg, Boothe & Cole, supra note 114, at 994. One recent
study, on the other hand, showed a "trend towards spending less time in
hospital after their release" among drug-treated patients when compared
with those who received psychotherapy or milieu therapy. May, Tuma,
Yale, Potepan & Dixon, Schizophrenia-A Follow-up Study of Results
of Treatment; II. Hospital Stay Over Two to Five Years, 33 ARCH. GEN.
PSYCHrAT. 481, 486 (1976).
129. Bockoven & Solomon, Comparison of Two Five-Year Follow-
Up Studies: 1947 to 1952 and 1967 to 1972, 132 AM. J. PSYCHIAT. 796
(1975).
130. Each study followed 100 patients of varying diagnoses. The
first study covered the years from 1947 to 1952 (before antipsychotic
drugs were generally available), and the second from 1967 to 1972. In
the earlier study, 34 of the 40 living schizophrenics on whom data was
available remained in the community; the other six returned to the hos-
pital. In the latter study, 30 out of 36 remained in the community, with
six again in the hospital. The earlier study's finding-that the vast ma-
jority of all psychiatric patients were surviving in the community after
five years-was an anomalous one at the time, when it was expected
that most mental patients would not return to the community. The
hospital in the earlier study did not altogether adhere to that, dogma
and encouraged independence. The authors of the earlier study thought,
prefiguring later writers, see note 139 infra and accompanying text,
that "[dj etention in the closed wards of mental hospitals may well have
contributed to the deterioration that was expected in schizophrenia."
Bockoven & Solomon, Five Year Follow-up Study of 100 Patients Com-
mitted to Boston Psychopathic Hospital, 251 N. ENG. J. MED. 81, 85 (1954).
131. The small number of subjects in the studies of course under-
mines this conclusion to some extent.
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These five studies are inconsistent with one another: we can-
not be sure whether drugs encourage, discourage, or have no
effect on a patient's independence. There are, however, diffi-
culties in even considering hospitalization or rehospitalization as
evidence of poor social functioning. One is that the process of
entry into a hospital appears to be random, not determined by
the degree of mental illness or social functioning. Another is
that hospitals may tend to breed dependence on the institution
among mental patients, so that what we may perceive as a symp-
tom of the illness is in fact a side-effect of the cure. Let us deal
with these matters one at a time.
First, there is evidence that the decision to hospitalize a
patient is determined by random situational factors. Taking 269
consecutive applicants to the psychiatric division of a metropo-
litan general hospital, Mendel and Rapport analyzed the deci-
sion to admit applicants as inpatients.13 2 They found that
the severity of illness was not a significant factor in admis-
sion since symptoms were as severe in those not admitted as in
those admitted. To some extent, the experience of the examiner
was a factor: those with the most experience admitted about one-
third fewer patients than those with the least experience.1 33
But, surprisingly, the most significant factors in admission were
whether the patient had been hospitalized before, 34 whether the
patient had friends, family or some organization that he could
turn to for help, 35 and the time of day that the patient
appeared. 36 To the extent these are random factors, we should
132. Mendel & Rapport, Determinants of the Decision for Psychiatric
Hospitalization, 20 ARcH. GEN. PSYCIAT. 321 (1969).
133. Those with less than six months of experience after their degree
and internship admitted 49 percent of the patients they saw; those with
more than three years experience admitted 32 percent. Id. at 323. Since
those with less experience are likely to be on the evening shifts, the ex-
perience and time of admission factors may be closely related, see note
136 infra and accompanying text. Mendel and Rapport, however, did
not analyze the data in a way which might show this relationship.
134. Among those who had been hospitalized before, 77 percent were
hospitalized; among those who had not been hospitalized before, the fig-
ure was 23 percent. There was no distinction in severity of symptoms
between those previously hospitalized and those not previously hospital-
ized. Id. at 324.
135. The interviewer in each case recorded on the admission form
the patient's "resources for support" from among ten different categories:
parents, spouse, children, siblings, friends, work, school, religious group,
political group, and club. Those with no resources for support were hos-
pitalized 63 percent of the time; those with three or more resources, only
35 percent. Id. at 322, 325.
136. During work hours, nine to five on weekdays, 32 percent of all
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question whether the fact of hospitalization indicates anything
about either illness or "general social functioning."'11 7 Hospitali-
applicants were admitted; during all other hours of the day and all day
on Saturdays and Sundays, 61 percent were admitted. This reveals an-
other phenomenon. As Mendel put it in a later talk:
Somebody comes to our emergency evaluation center at five
o'clock in the evening, schizophrenic, yes, but he has been schiz-
ophrenic all his life. Just dropped down from Phoenix, Arizona,
a little freaked out, wandering around, looking bizarre and the
police bring him in. We know what to do for him: put him
back on medication, give him support in our clinic. But the
clinic is closed. The social work agencies are closed. We can't
do anything until morning. So, we give him medication and put
him to bed overnight.
Mendel, Some Experiences with a Proprietary Service Organization, Re-
marks at 24th APA Institute of Hospital and Community Psychiatry, St.
Louis, at 4 (1972) reprinted in edited form as Curricular Reprint Series
No. 104, Dep't of Psychiatry, Northwestern University School of Medi-
cine [hereafter cited as Mendel, Remarks].
Mendel's solution to his problem is clever enough to be worth men-
tioning. Knowing that if seen the next morning, fully one-third of those
admitted during the previous night would be immediately released, see
Mendel & Rapport, supra note 132, at 327, and that the cost of admitting
someone overnight to the hospital was about $200, Mendel sought an eco-
nomical solution to the problem:
You can go to a mighty nice hotel and live it up for $200. Be-
cause of our problems of crowding, we did just that.
Somebody made a big mistake and built the Holiday Inn across
the street from LA County Hospital They weren't able to fill
it, and so we were able to work out a contractual agreement
to use 30 rooms a night at $15 a room. We would see patients
in our emergency room, give them medication, and house them
in the Inn. Since the Inn was across the street, we could guar-
antee that if anybody got upset, we would have someone over
there in two minutes. All they had to do was just let the people
go to bed. Now we were able to put people to bed at $15 in-
stead of $200. No magic, no psychiatric secrets, just the simple
logic of economics.
Mendel, Remarks, supra at 4.
137. Of course, some of these apparently situational factors may well
have a personal component. Why is a person without resources? Is it
just luck, or does he do something that alienates him from other people?
And why have the police brought him in? There is even the possibility
that the patient has a subconscious desire to get into a hospital and that
that is why he gets admitted. Mendel and Rapport's statistics cannot
show how the applicant may have subtly manipulated the decisionmak-
ers to admit him. It would make sense for someone without a bed to
sleep in to go to a hospital where he knows he can get one.
This question of patient voluntariness also points up another defect
in the drug efficacy studies. Although it is a truism of psychiatry that
the patient's desire for treatment will always affect outcome, drug re-
searchers have not tried to distinguish those who desire to be in a hos-
pital from those who do not. They do not generally consider it worth
reporting whether or not the patients they are treating are voluntary
or involuntary. Perhaps in the case of long-term schizophrenics volun-
tariness is not a factor; the patient may have been in the institution so
long that he has no real conception of any other way of life.
But at least one study has suggested that for some patients in some
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zation may be a better indicium of the social environment and of
society's tolerance for unusual people than it is of a patient's
level of functioning.
13 8
Second, the fact that many schizophrenics remain in hos-
pitals for long periods of time or return again and again to
hospitals may not be evidence of the process of disease or of the
inability of schizophrenics to exist in society; it may be evidence
of what the hospitals do to patients. A number of observers of
situations the voluntariness of admission may be a significant factor in
the outcome of treatment. A re-analysis of the Cole study data on acute
schizophrenics discussed in text accompanying notes 64-68, NIMH-PRB
Collaborative Study Group, Short-Term Improvement in Schizophrenia:
The Contribution of Background Factors, 124 AM. J. PSYcHIAT. 900
(1968), showed that among the placebo patients, voluntariness of hos-
pitalization, rated on a five-point scale (1 = patient in favor of hospital-
ization; 5 = patient opposed), showed a higher positive correlation with
positive outcome than any other factor. While the correlation was not
tremendously high (.235), and there was virtually no correlation among
the drug patients, this study does corroborate the popular psychiatric no-
tion that a voluntary patient will do better than an involuntary one.
And it does suggest that voluntariness and the circumstances surround-
ing admission to the hospital ought to be part of every drug study.
138. A striking example of community tolerance of the mentally ill
exists in Gheel, a Flemish village of about 20,000, which has long had
a tradition of caring for the mentally ill. Legend has it that in 700 A.D.
a beautiful Irish princess, Dymphna, fled there to escape her incestuously
inclined father. Unfortunately for her, she ran neither far enough nor
fast enough, and when her father caught her, he beheaded her. The prin-
cess was canonized for her noble effort to avoid a fate worse than death,
and word spread that the reliquary containing her bones would exorcise
the devil which caused insanity. Those possessed flocked to Gheel, and
by the mid-thirteenth century a tradition of family care of the mentally
ill who came but were not cured was well established in Gheel. By
1851, one out of every eleven inhabitants of the city and surrounding
farms was mentally ill: one thousand out of a total population of eleven
thousand. Earle, A Visit to Gheel, 8 Am. J. INSANITY 67 (1851).
In 1960, when the town's population had grown to 20,000, there were
2,100 mental patients in family care, of whom 29 percent were schizo-
phrenic.
The patients, comprising a tenth of the population, are not
treated as a separate class. I have seen coffee served in a cafe
with as much deference to actively hallucinating psychotics as
to anyone else. There are two movie theatres in the town and
on a Sunday evening there are as many patients as townspeople
in them. I never saw any revulsion or fear displayed towards
patients, although many of them act in a bizarre fashion. About
a half a dozen incidents of violence have occurred in the past
25 years, two of which resulted in fatalities. Although these
were no secret to the populace there was no outcry for more
controls.
Dumont & Aldrich, Family Care After a Thousand Years-A Crisis in
the Tradition of St. Dymphna, 119 AM. J. PsYcnIAT. 116, 117 (1962). Ob-
viously a difference between the social functioning of a mental patient




the process by which a person enters the enclosed world of the
mental hospital have concluded that the process is designed to
isolate the individual and make him a part of the hospital social
structure, dependent on the hospital to fulfill all his needs-in a
word, institutionalized. 139 If the patient who enters the hospital
is confused and emotionally upset, he may be particularly vul-
nerable to this kind of influence. A temporary commitment may
create a permanent patient or one who reverts easily to being
a patient when the strain of living outside of an institution
becomes great.
There is some objective evidence for this theory. Two British
psychiatrists examined three London mental hospitals and dis-
covered that a relatively high degree of social complexity in the
institution was associated with a shorter average length of stay
and a lower re-admission rate.140  In other words, when the
patient does for himself in the hospital, he is able to do for him-
self out of the hospital. Complementing this finding are studies
that have shown that treatment in a milieu less restrictive than
the closed ward of a hospital produces better results. In a con-
trolled study in a New York hospital, patients of various diag-
noses were randomly assigned to inpatient or day patient (spen-
ding their nights at home) status; otherwise they received the
same treatment. The day patients spent a shorter time in the
hospital, were less frequently hospitalized, and lost their psychi-
atric symptoms more rapidly than the inpatients. 141 There were
similar results in a Wisconsin clinic that randomly assigned in-
coming patients to inpatient or outpatient care. 42
139. See E. GOFFMAN, AsYLUIms (1962); D. ROTHMAN, THE DISCOVERY
oF THE AsYLum (1971); Gruenberg, The Social Breakdown Syndrome-
Some Origins, 123 Am. J. PsYcIAT. 1481 (1967). See also Chambers,
Alternatives to Civil Commitment of the Mentally IIl: Practical Guides
and Constitutional Imperatives, 70 MIcH. L. REv. 1107, 1127-33 (1972)
and the sources cited therein.
140. J. WING & G. BROWN, INsTITUTIoNALISm AND SCHIZOPHRENIA
(1970). Social complexity was quantified as the number of different
places within the hospital that the patient went during a day, the number
of work assignments, the number of choices made by the patient in the
course of a day, the number of visitors and the number of off-ground
visits without a staff person.
141. Herz, Endicott, Spitzer & Mesnikoff, Day Versus Inpatient Hos-
pitalization: A Controlled Study, 127 Am. J. PSYCHIAT. 1371 (1971).
Contra, Michaux, Chelst, Foster & Pruim, Day and Full-Time Psychiatric
Treatment: A Controlled Comparison, 14 CuR THER. REs. 279 (1972).
142. Stein, Test & Marx, Alternative to the Hospital: A Controlled
Study, 132 Am. J. PSYCHIAT. 517 (1975); Stein & Test, Training in Com-
munity Living: One Year Evaluation, unpublished paper presented at
American Psychiatric Association Meeting in Anaheim, Calif., May 5,
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Conversely, if we break the routine of the hospital for inpa-
tients, we may find that many patients who were thought incura-
bly maladjusted are in fact able to exist outside of institutions. A
group of researchers in Wisconsin, for example, treated the social-
ly unacceptable behavior of chronic schizophrenics not as an in-
voluntary product of their illness, but as purposive, voluntary
behavior designed to manipulate their hospital environment and
to relieve them of responsibility. The staff punished this behavior
and generally tried to discourage it. As a result 60 percent of the
"hopeless" patients abandoned their socially unacceptable beha-
vior and were released to the community during the period of
the study.1 43 All these studies suggest that the danger of creating
a dependence on institutions ought properly to be thought of as
one of the risks of treatment in schizophrenia.
To be fair to the hospitalization studies, I think one must
admit that they do show that drugs affect behavior in some way-
behavior which leads one back to a mental hospital. But since
we are unsure what behavior it is that causes someone to enter,
to re-enter, or to be committed to a mental hospital, we cannot
say with any certainty what the scope of the drug effect is.1 4 4
Hence we must conclude that these studies do not provide evi-
dence of a benefit that is in any way comparable to the life-
saving benefit present in Georgetown or to the immunity from
a deadly disease present in Jacobson.
E. FACTOR THREE: WHAT ARE THE DANGERS INVOLVED IN TREAT-
MENT WITH THE ANTIPSYcHOTIc DRUGS?
A number of side effects seem to occur in many, if not most,
patients treated with antipsychotic drugs. 1 45 For the most part
1975. After both four months and a year those who had received the
outpatient care had better global ratings on symptomatology, spent less
time in institutional living conditions, and were less often unemployed
than those who received the inpatient care. The difference in employ-
ment, however, was not among those independently employed, but grew
out of the fact that about a quarter of the outpatient group was in shel-
tered employment and only one to five percent of the inpatient group
was in sheltered employment.
143. A. LUDWIG, TREATING THE TREATMENT FAnLuREs: THE CHALLENGE
OF CHRONIC SCHIZOPHRENIA (1971).
144. Use in the studies of a term like "clinical deterioration," see Ho-
garty & The Collaborative Study Group, supra note 121, at 603, makes
it sound as though the standard for relapse was one based entirely on
intellectual and verbal behavior.
145. The following discussion is essentially a synopsis of KLEIN &
DAVIs, supra note 34, at 94-116.
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these side effects are temporary and annoying. At the outset
of the drug treatment, but usually not past the first two weeks,
patients may feel drowsy; they may also experience a number
of annoying autonomic nervous system effects-"dizziness, faint-
ness, weakness, dry mouth, throat and eyes, nasal congestion,
nausea, vomiting, constipation, diarrhea, urinary disturbances,
blurred vision,"'146 and others.
There are also three categories of effects on the central
nervous system, called extrapyramidal side effects: 147 Parkinson-
ism, whose symptoms, like muscle rigidity and tremor, mimic
Parkinson's disease; 1 48 distonias and dyskinesia, which consist of
uncoordinated spastic body movements; and akathisia, a restless-
ness characterized by pacing and fidgeting. These side effects
develop within the first few days of treatment with antipsychotic
drugs. They can generally be relieved by the drugs which are
used to treat Parkinson's disease and cease with termination of
the antipsychotic medication.
The more serious side effects are of several varieties. Some
patients are allergic to the drugs. About one patient in 1000,
for example, will develop a benign jaundice that disappears
146. KLEIN & DAvIs, supra note 34, at 102-03. These effects all ap-
pear in widely varying incidences, with the variation probably due to
differences in the observer's definitions. For example, drowsiness was
reported in one study to occur in 96 percent of patients, Blair & Brady,
Recent Advances in the Treatment of Schizophrenia: Group Training
and the Tranquilizers, 104 J. MENT. SC. 625 (1958), while another study
found drowsiness in less than 10 percent of the patients, Goldman, The
Results of Treatment of Psychotic States with Newer Phenothiazine
Compounds Effective in Small Doses, 235 Am. J. ME. Sci. 67 (1958).
In any case it is likely that any given patient will display some of
the side effects associated with the antipsychotic drugs. See KLEIN &
DAVIs, supra note 34, at 96-97, table 9, (listing incidence of side effects
by drug; statistics produced by combining all studies). The incidence
of some of the most common side effects were set forth in the Cole study,
see note 70 supra.
147. They received this name because they affect the extrapyramidal
nervous system, a nonvoluntary nervous system controlling functions
like body posture and the coordination of voluntary movements. It is
distinguished from the pyramidal system, which passes through part of
the brain in bunches of nerves called pyramids and controls voluntary,
learned, motor activity. See J. CHUSID, CORRELATIVE NEUROANATOMY &
FUNTIONAL NEUROLOGY 16 (15th ed. 1973); A. GATZ, ESSENTIALS OF CLIN-
ICAL NEUROANATOMY AND NEUROPHYSIOLOGY 7-9, 110, 119-23 (4th ed. 1970).
148. The effect is to mimic, not to create, Parkinson's disease. One
student piece appears to confuse the syndrome, which is temporary, with
the disease, which is permanent and degenerative. See Note, Condition-
ing and Other Technologies Used to "Treat?" "Rehabilitate?" "Demol-




within a few weeks, although on rare occasions the liver may
function abnormally for as long as six months or a year.1 49 Other
side-effects, three in particular, appear regularly: skin and
eye changes, tardive dyskinesia, and agranulocytosis. Eye and
skin effects are related to high dosage, long therapy, or both, and
appear in from one to thirty percent of all patients receiving anti-
psychotic drugs. The skin may become quite sensitive to sun-
light and turn gray, blue, or purple on exposure to the sun.
In the eye, fine particles may appear in the lens and cornea and
grow to areas of opacity. In some cases these opacities may
persist for as long as six months after cessation of drug therapy.
Tardive dyskinesia is an extrapyramidal syndrome common
among patients who have received antipsychotic medication for
long periods of time. It is
characterized by . . . sucking and smacking movements of the
lips, inconsistent lateral jaw movements, as well as the rhythmi-
cal forward and backward (sometimes lateral) movement of the
tongue ("fly-catcher movement"). Other parts of the body are
usually only mildly affected. Choreiform-like movements can
occur, with jerky sometimes athetoid movements of the extremi-
ties, particularly of the fingers, ankles and toes. Tonic contrac-
tions of the neck and back muscles are sometimes seen.
Swallowing may become a problem with consequent weight loss.
There may be disturbances in respiratory rate, rhythm and
amplitude.150
The syndrome may persist for years, even if the patient stops
taking the drug. Curiously, cessation of the drug may also pre-
cipitate tardive dyskinesia. Although the syndrome sometimes
disappears with even higher doses of phenothiazines, there is as
yet no effective treatment for it. 151
149. Davis & Cole, Antipsychotic Drugs in 2 CTP/II, supra note 47, at
1936-37.
150. KLEIN & DAVIS, supra note 34, at 99. In the studies Klein and
Davis surveyed, researchers discovered tardive dyskinesia in anywhere
from 5.2 percent to 24.7 percent of chronically hospitalized patients; the
average from all of the studies was 18 percent. Id. at 99-100. Crane's
survey of more recent literature (17 studies between 1967 and 1971)
showed a frequency of from 0.5 percent to 40 percent. Crane, Persistent
Dyskinesia, 122 BRIT. J. PSYCHAT. 395, 396 table 1 (1973). While many
of these studies deal with chronic, old patients, in whom the syndrome
could be due to such causes as age or neurological disease, the syndrome
seems to appear most often among long-term inpatients who have been
taking antipsychotic drugs. On the basis of its high incidence in this
latter group and its infrequency among the untreated, Crane con-
cluded that there was "compelling evidence to indicate that tardive dys-
kinesia is related to the use of phenothiazines or similar agents." Id.
at 397.
151. Gardos & Cole, Maintenance Antipsychotic Therapy: Is the Cure
Worse than the Disease? 133 Am. J. PsYc-mAT. 32 (1976).
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These two side effects, skin and eye changes and tardive
dyskinesia, must be considered predictable risks in treatment,
particularly in long term or high dosage treatment. 1 52
The third, and most serious, side effect is agranulocytosis,
which involves a precipitate disappearance of white blood cells
and consequent exposure to immediate infection. It usually
appears within the first six weeks of treatment and is fatal in
30 percent or more of the cases; 15 3 if the patient survives the
initial phase and treatment is stopped, the blood becomes normal
in about seven to ten days. If we accept Hollister's estimate that
agranulocytosis will occur in one out of every 3000 patients
treated with chlorpromazine "5 4 and that 30 percent of the cases
152. Leff and Wing concluded:
There are definite hazards associated with long-term phenothia-
zine treatment. Irreversible and incapacitating dyskinesias can
develop, serious pigmentation of the cornea and lens can occur,
and there have been reports of cardiac vascular complications.
. . These are cogent reasons for attempting to expose as few
people as possible to long-term phenothiazines.
Leff & Wing, Trial of Maintenance Therapy in Schizophrenia, 3 BRIT.
MED. J. 599, 603 (1971) (emphasis added).
153. Davis & Cole, Antipsychotic Drugs in 2 CTP/II, supra note 47, at
1937.
154. Hollister, Complications from Psychotherapeutic Drugs-1964, 5
CLn . PHARMACOL. & THER. 322, 325 (1964). A number of authors speak
of the risk as "relatively small," Baldessarini & Lipinski, Risks vs. Bene-
fits of Antipsychotic Drugs, 289 N. ENOL. J. MED. 427, 428 (1973), while
others refer to it as "not infrequent." Ananth & Beszterczey, Treatment
of Psychosis Subsequent to Phenothiazine-Induced Agranulocytosis, 14
COMPR. PSYCHIAT. 319, 322 (1973). While exact figures may be hard to
come by, Davis and Cole's estimate of the incidence at "about one out
of 500,000 patients," Davis & Cole, Antipsychotic Drugs in 2 CTP/II,
supra note 47, at 1937, seems unduly sanguine and is belied by the fact
that by June 1965, the Panel on Hematology of the American Medical
Association Registry on Adverse Reactions, Council on Drugs, had ac-
cumulated 138 reports of agranulocytosis in cases where the only drug
involved was a phenothiazine. Pisciotta, Agranulocytosis Induced by
Certain Phenothiazine Derivatives, 208 J.A.M.A. 1862, table 1 (1969). If
Davis and Cole are correct, then at least 69 million persons had been
treated with phenothiazines by that date. Yet only about one percent
of the population is thought to be schizophrenic, see Falek & Moser, Clas-
sification in Schizophrenia, 32 ARCH. GEN. PSYcEMAT. 59, 60-61 (1975).
The studies Klein and Davis surveyed led them to estimate the incidence
at 0.32 percent for patients receiving chlorpromazine, the antipsychotic
drug for which, because of its popularity, most information is available.
KLEIN & DAVIs, supra note 34, at 96, 115-16. See Carfagno & Magee,
Granulocytopenia Due to Chlorpromazine, 241 AM. J. MED. Sci. 44 (1961)
(11/1000 over four year period); Pisciotta, Ebbe, Lennon, Metzger &
Madison, Agranulocytosis Following Administration of Phenothiazine
Derivatives, 25 AM. J. MED. 210 (1958) (18 cases among 3,000 patients).
Moreover, the most careful study I have found, which was based on
37,400 leukocyte counts made over an eight-year period on 6200 clinic
patients receiving phenothiazines, specifically intended to discover agra-
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are fatal, then there is one chance in 10,000 that a patient
treated with chlorpromazine will die from that treatment. The
chances of a fatal outcome are small, but certainly not inconsider-
able, especially when we are considering imposing the treatment
over the patient's refusal.
In addition to these purely physical dangers, certain social
dangers must be reckoned with in evaluating drug treatment of
schizophrenics. I have already mentioned that the danger of in-
stitutionalization-becoming dependent on a mental hospital
-should be considered one of the dangers of hospitalization and
treatment. Another similar danger is that since the drug effect
is not a permanent one, we will have to confine an involuntarily
treated schizophrenic indefinitely in an institution or elsewhere.
The action of the drugs is less like that of an antibiotic, which
cures an infection and no longer need be taken, than like that
of a diabetic's insulin, which he must take all his life to maintain
his body's chemical balance. 155 While some schizophrenics in all
nulocytosis, found five cases, or one per 1240 patients. Pisciotta,
Agranulocytosis Induced by Certain Phenothiazine Derivatives, supra at
1864. If anything, then, the Hollister estimate seems conservative.
155. Klein and Davis report that all the adequate studies that have
investigated the matter show that when an active antipsychotic drug is
replaced by placebo under double-blind conditions, there is a significant
increase in symptoms. KLEIN & DAvIs, supra note 34, at 68-72. Again,
all but two of the nine studies they report were concerned with long-
term patients-and the difference between those patients and our hypo-
thetical patient may be quite significant-but two studies, one of which
is included in Klein and Davis's compendium, do confirm the thesis that
a withdrawal of antipsychotic drugs will result in a recurrence of symp-
toms in schizophrenic patients other than those chronically hospitalized.
Gross and his co-workers studied a group of 90 outpatients, 82 of
whom were schizophrenics, some of whom had been long-term inpatients,
and all of whom were receiving antipsychotic drugs (over two-thirds
of them for more than two years). See Gross, Hitchman, Reeves, Law-
rence & Newell, Discontinuation of Treatment with Ataractic Drugs, 116
Am. J. PSYcHIAT. 931 (1960). The experimental group, consisting of 56
patients, received smaller and smaller doses of their drug in identical
capsules, until they were finally, after a period ranging from four weeks
to five months, receiving only a placebo; control patients continued to
receive a maintenance dose of drugs. Over a seven month period, under
double-blind conditions, 41 of the 56 experimental patients (73 percent)
relapsed-17 relapses occurring during the period of withdrawal-while
only three of the 34 controls (9 percent) relapsed. Leff and Wing
studied a group of 30 British patients nonrandomly selected out of a pool
of 116 patients who had recovered from an attack of acute schizophrenia
and were receiving maintenance doses of antipsychotic drugs. See Leff
& Wing, supra note 152. In a double-blind trial 10 of 12 patients (83
percent) on placebo relapsed, while only six of 18 drug patients (33 per-
cent) relapsed within one year. As Leff and Wing point out, the differ-
ence between American and British diagnostic practices "renders difficult
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studies survive in the community without drugs and without the
recurrence of symptoms,156 others relapse when they stop tak-
ing drugs. Moreover, available studies show that a large per-
centage of patients receiving antipsychotic medication will stop
any comparison between American and British studies on schizophrenia,"
id. at 599, but since their study confirms the results reached in all Amer-
ican studies, and since the British diagnosis of schizophrenia tends to
be narrower than the American, it is fair to use this study as a proof
of the effect of withdrawal of drugs on most American schizophrenics.
The success of the antipsychotic drugs with schizophrenics and the
fact that withdrawal leads to a reappearance of symptoms have spawned
a number of etiological hypotheses about schizophrenia that postulate
a long-term chemical imbalance or deprivation. See, e.g., Stein & Wise,
Possible Etiology of Schizophrenia: Progressive Damage to the Norad-
renergic Reward System by a 6-Hydroxydopamine, 171 SCIENCE 1032
(1971).
156. See, e.g., Hogarty, supra note 102. (20 percent of all placebo
patients survive in community after two years). There seems as yet to
be no reliable way to tell which patients will survive on placebo. For
example, the Downstate research team attempted to produce a scale that
would predict which schizophrenic outpatients receiving a placebo would
eventually be rehospitalized. See Rosen, Engelhardt, Freedman, Mar-
golis, Rudorfer & Paley, Prediction of Psychiatric Hospitalization, 80 J.
ABN. PSYCHOL. 271 (1972). They tested their scale on 149 patients who
were seen by their clinic from a minimum of two weeks to a maximum
of 109 months. Of those predicted to be "hospital prone," 56.5 percent
ended up in the hospital; of those predicted non-prone, 10.5 percent. The
sample they dealt with had about 60 percent predicted hospital prone,
but other of the Downstate group's publications indicate that the normal
incidence of hospital prone patients is 25 to 30 percent of the schizo-
phrenic population. See Engelhardt, Rosen, Freedman & Margolis, Phe-
nothiazines in Prevention of Psychiatric Hospitalization, 16 ARcH. GEN.
PSYCIAT. 98 (1967). If that is the case, then testing a sample of 100
schizophrenics will produce a group of 25 who are labelled hospital-
prone, of whom 14 will actually be hospitalized within a period of about
five years. (No figure on average length of treatment is given in the
Rosen article; this is a rough mean taking the minimum period, two
weeks, and the maximum, 109 months, that a patient might have
remained in the study.) Among the seventy-five who are predicted non-
prone, eight will be hospitalized. Such a test is reasonably accurate; it
identifies 14 out of 22 who will actually go into the hospital (64 percent).
On the other hand, it also predicts that 11 will be hospitalized who in
fact will not. Thus it is not a test upon which we would want to base
a legal decision. We would not, for example, want to extend indefinitely
the care and confinement of the hospital-prone on the basis of our suspi-
cion that they need continuing treatment; that would mean unnecessarily
confining thirteen patients out of every one hundred. Where liberty is
in the balance, we ought to require a higher degree of accuracy. More-
over, taking drugs will not necessarily prevent relapse in all cases.
Although other research indicates that drugs may prevent hospitaliza-
tion under some circumstances, see text accompanying notes 123-24 su-
pra, the Downstate group discovered in the Rosen study that the percent-
age of the hospitalized was marginally higher among those receiving
chlorpromazine (59.4 percent) than among those receiving placebo (56.7
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taking it once they are out of the hospital.15 This fact neces-
sarily belies one or the other of two assumptions implicitly relied
on by those who would confine and involuntarily treat the men-
tally ill because they are incompetent-that if they were com-
petent they would take their drugs, and that if they took the
drugs they would become competent. Thus, assuming we are
willing to incarcerate the patient in the first place in order to
administer drug treatment, we must be ready to incarcerate him
again when he fails to take his drug outside the hospital. And in-
deed, as attendance at a mental health court might demonstrate,6 8
many of the patients now returning again and again to mental
hospitals (the "revolving door syndrome," as it has been termed)
have refused or neglected to take medication and are returned
to the hospital solely in order to resume drug treatment.
The logic of the parens patriae position could lead us even
further-to maintain that when a patient refuses to take medi-
cation that has had a beneficial effect in the past, we ought to
commit him indefinitely.' 59 We should recall at this point that
tardive dyskinesia and the skin and eye problems mentioned
above are associated with the long-term treatment that such a
commitment would involve.16 0
A third type of danger associated with the involuntary treat-
ment of schizophrenia inheres in the vagaries of the diagnostic
process. If it is true, as Ennis and Litwack contend,' 6' that
percent). Thus it appears that use of the drug by those who are likely
to go back into the hospital has almost no relation to actual rehospitaliza-
tion.
157. See The Collaborative Study Group, supra note 112 (138 out
of 374 outpatients in study ceased taking or were grossly irregular in
taking their medication within the first year of study). This is at least
some evidence of error in the assumption, see Stone, Comment, 132 Am.
J. PSYcHiAT. 829 (1975), that the treatment imposed upon a patient is
something he would choose for himself were he compos mentis. The
drug putatively renders him competent to make decisions, yet in the Ho-
garty study over one-third of those competent decisions were to stop
taking drugs.
158. I have observed mental health court judges who, when faced
with a former mental patient who admits some trivial delusional symp-
tom (e.g., that he believes the FBI is controlling his activities via a de-
vice implanted in his brain), will commit the patient anew in order to
get him to take his medication. I have also seen judges willing, in simi-
lar cases, to forego commitment on the promise of the patient and, almost
invariably, his attorney, that he will take medication.
159. A less drastic version of this position, that we commit the pa-
tient until he promises to take his medication, implies a purely coercive
use of the hospital and is no less distasteful.
160. See note 152 supra.
161. See Ennis & Litwack, supra note 31, at 702.
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the chances that two psychiatrists will agree on a specific diagno-
sis are about 40 percent, then a serious equal protection problem
arises from the fact that selection for involuntary treatment will
to a large extent depend on the totally random and irrelevant
factor of which psychiatrist happens to be doing the diagnosing.
If the literature were arranged in such a way that one could
tell which characteristics or behaviors drug treatment will mod-
ify, then one might be able to deal with the diagnostic variation
by selecting patients on the basis of "curable" characteristics
and not on the basis of diagnosis. But unfortunately, the litera-
ture primarily describes research subjects by diagnosis and
proves effectiveness by overall assessments of psychiatric state.
Another problem related to the diagnostic process is that if
we employ diagnostic criteria other than those used by the re-
searchers in the studies, we have no assurance that the patients
treated, although plausibly labelled schizophrenic, will react as
did those in the studies. Psychiatrists involved in research may
tend to agree as to diagnosis more often than Ennis and Litwack
would indicate,162 but that is no guarantee that the public mental
hospital's diagnoses will be anything like the researchers' diag-
noses. Those who make the diagnoses in the experimental situa-
tion are trained researchers, probably the cream of the psychi-
atric crop, and may share assumptions about schizophrenia. The
psychiatrist in a public mental hospital is likely to be less well
qualified and to make different kinds of diagnoses. 6 All in all,
there seems to be a fairly substantial risk that our hypothetical
patient will differ significantly from those on whom treatment
has been shown effective.
F. FACTOR FouR: WHAT ARE THE DANGERS OF FAILING TO TREAT?
This section deals with the inherent dangers of schizophrenia
to the patient and to society. There is very little evidence about
162. See note 71 supra.
163. There is some concrete evidence that research psychiatrists and
public hospital psychiatrists diagnose patients differently. Of 247 con-
secutive patients admitted into a psychiatric ward of a New York general
hospital, 41 were diagnosed as paranoid schizophrenics. Researchers
found, though, that only two of those 41 satisfied "research criteria" for
schizophrenia. Abrams, Taylor & Gaztanaga, Manic-Depressive Illness
and Paranoid Schizophrenia, 31 ARCH. GEN. PSYCHIAT. 640 (1974). See
also Morrison, Clancy, Crowe & Winokur, The Iowa 500: Diagnostic
Validity in Mania-Depression and Schizophrenia, 27 ARcH. GEN.
PsYcmiAT. 457 (1972). This does not prove that either set of diagnosti-
cians were right or wrong, but it does prove that psychiatric researchers
and practitioners do not share a common set of diagnostic criteria.
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this aspect of schizophrenia; what there is concerns crime and
suicide rates among schizophrenics. Since crime and suicide are
quintessential examples of behavior harmful to patient or soci-
ety, it is fair to examine the evidence with regard to them to
discover whether schizophrenics as a class are more dangerous
than are members of the general public. In general, it appears
that schizophrenics commit suicide and serious crimes at slightly
higher rates than the general population, but not at rates high
enough to justify involuntary treatment. Moreover, I have
found no evidence that drug treatment of schizophrenia in any
way reduces suicide or crime rates among schizophrenics.
Serious crime among schizophrenics: The evidence that
schizophrenics commit crime at rates significantly different from
the non-schizophrenic members of the population is slight.18 4
The studies focus either on the incidence of mental illness among
criminals or on the incidence of crime among the mentally ill.165
Studies of 223 randomly chosen convicted criminals handled by
the Missouri Department of Probation' 66 showed only one per-
cent schizophrenic'6 7-the same percentage as in the general pop-
ulation. And even if the study had included as psychotic those
criminals who had avoided the Probation Department because
164. Guze, reporting after a review of the literature, concluded that
"[t]here is no complete agreement as to whether any of these condi-
tions [psychosis, schizophrenia, primary affective disorder, or the var-
ious neurotic disorders] is more common among criminals than the
general population, but it is clear that these disorders carry only a
slightly increased risk of criminality if any at all." S. Guz., CRIMINAL TY
AND PSYCHIATIC DISORDERS 130 (1976).
165. Because of my belief that arrest rates are a poor indicium of
the commission of crime, I do not intend to deal with studies concerning
the arrest rates of former mental patients. Arrest only indicates that
police suspect the commission of a crime. Moreover, as we know from
the fact that they often enter the hospital in the company of a police-
man, see Gilboy & Schmidt, Voluntary Hospitalization of the Mentally
Ill, 66 Nw. U.L.R. 429, 440 (1971), mental patients make police suspicious.
And at any rate, the general conclusions of the studies concerning arrest
rates are not significantly different from the conclusions in the text:
mental patients or schizophrenics, as compared with the general pooula-
tion, are arrested at the same or at only slightly higher rates. See Zitrin,
Hardesty, Burdock & Drossman, Crime and Violence Among Mental Pa-
tients, 133 Am. J. PSYCHIAT. 142 (1976) (reviewing literature and report-
ing study at Bellevue Hospital in New York).
166. Guze, Goodwin & Crane, Criminality and Psychiatric Disorders,
20 ARCH. GEN. PSYCHIAT. 583 (1969); Guze, Tuason, Gatfied, Steward &
Picken, Psychiatric Illness and Crime with Particular Reference to Al-
coholism: A Study of 223 Criminals, 134 J. NERV. & MENT. Dis. 512 (1962).
1G7. One felon was diagnosed schizophrenic in both studies; two oth-
ers were found schizophrenic in one study but not the other. See Guze,
Goodwin & Crane, supra note 166, at 588.
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either an insanity plea or the development of insanity during
imprisonment had sent them to the state hospital for the crim-
inally insane, the "combined prevalence [of schizophrenics and
other psychotics would not have been] very different from that
expected in the general population."' 6 8 A similar study con-
ducted in the Netherlands reached much the same conclusion.169
Perhaps even more striking is a study of 500 consecutively
admitted patients at a Washington University psychiatric
clinic.170 Although four percent of the group had felony convic-
tions, none of the more than 200 diagnosed as suffering from
schizophrenia, schizophreniform illness, or affective disorder was
among that four percent. While it is unclear whether it is
the felony-committing non-schizophrenics or the non-felonious
schizophrenics who are abnormal, since the study gives no com-
parison with the population at large, the study at least strongly
suggests that there is no tie between schizophrenia and criminal
acts.
These studies, however, fail to account for those persons who
have committed crimes but leave the criminal system prior to
conviction because of either incompetence to stand trial or incar-
ceration via civil commitment. This may well be a significant
number of those who enter the criminal system.' 7' Also the
studies do not take into account those persons whose criminal
conduct is never detected or prosecuted. One careful West Ger-
man study seems to have taken these problems into account. 172
The researchers focused on violent offenses, where the rate of
solution was over 90 percent and where there would be a high
likelihood of discovering psychopathology. Moreover, they did
not confine their survey to court and police records, but also
drew cases from the records of the state mental hospitals where
168. Id., at 589.
169. Among a population of 500 convicted Dutch criminals whom the
court had sent to a psychiatric clinic for evaluation prior to sentencing,
only one clear diagnosis of schizophrenia emerged. Kloek, Schizophrenia
and Delinquency: The Inadequacy of Our Conceptual Framework, in
THE MENTALLY ABNORMAL OFFENDER 19 (A. de Reuck &.- R. Porter eds.
1968) (citing author's study appearing at 67 FOLIA PSYCHIATRICA NEURO-
LOGICA ET NEuROCHMURGICA NEERLANDICA 176 (1964)).
170. See Guze, Woodruff & Clayton, Psychiatric Disorders and Crim-
inality, 227 J.A.M.A. 641 (1974).
171. In 1967, 52 percent of those in state mental hospitals who had
arrived through the criminal justice system were there prior to convic-
tion. P. ScHEIDEMANDEL & C. KANNO, THE MENTALLY ILL OFFENDER 20
(1969).
172. See Haefner & Boeker, Mentally Disordered Violent Offenders, 8
SOCIAL PSYCHmAT. 220 (1973).
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offenders went for treatment, preventive detention, or evalua-
tion. They discovered that although the combined incidence of
psychosis, retardation, or severe organic brain syndrome among
the violent offenders was the same as in the population at large,
schizophrenia appeared among the violent offenders 1.7 times
more often than one would have expected in a random sample
of the population. The absolute rate of violent crime among
schizophrenics, however, was still quite low. There were five
violent offenders per 10,000 schizophrenics over a ten-year period.
Obviously we cannot apply these statistics wholesale to the
situation in this country; our nation has much more violent crime
than West Germany, and an annual rate of five violent crimes
per 10,000 among schizophrenics would be much lower than the
rate in the American population at large.'73 But if American
schizophrenics, like German schizophrenics, committed violent
crimes at 1.7 times the national rate, this would mean, on the
basis of 1973 figures, for example, that one American schizo-
phrenic out of every 6325 would commit a murder.174 Assuming,
for the sake of argument, that drug treatment would reduce this
rate to that present in the population in general-a matter of
173. In 1960, about the middle year for the Haefner and Boeker
study, the murder rate for the United States was 5 per 100,000 population
and the aggravated assault rate was 60 per 100,000, a total of 6.5 serious
violent crimes per 10,000. BUREAU OF THE CENSUS, UNITED STATES
DEP'T COMMENCE, THE STATISTICAL ABSTRACT OF THE UNITED STATES 140
(1972) [volumes in this series will hereafter be cited as STATISTICAL
ABSTRACT, giving the year of publication]. While there may have been
a lower rate of violent persons in the population, since one person may
h we committed more than one murder or more than one aggravated as-
.. ult, one can nonetheless be fairly certain that the incidence of violent
persons is higher here than among West German schizophrenics.
174. This is based on the reasonable assumption that one person
commits one murder, see UNITED STATES DEP'T OF H.E.W., THE VIOLENT
OFFENDER 35 (1966), so that the 1973 murder rate of 9.3 per 100,000 pop-
ulation is equivalent to a murderer rate of 9.3 per 100,000. FEDERAL Bu-
REAU OF INVESTIGATION, UNITED STATES DEP'T JUSTICE, CRIME IN THE UNITED
STATES: 1973, at 6 (1974) [hereafter cited as CRIME]. This translates
to one murderer per 10,752 persons in the United States.
The incidence of murderers is lower among schizophrenics than it
is among black persons, who comprise 58 percent of the murder arrestees,
id. at 10, but only 11.3 percent of the population, STATISTICAL ABSTRACT,
supra note 173, at 26 (1974). If we assume that arrest rates correlate
with murderer rates, this produces a murderer rate over five times the
national average. Similarly, young persons between the age of 20 and
24 comprise 25 percent of the murder arrestees, CRIME, supra at 10, but
only 6.8 percent of the population, STATISTICAL ABSTRACT, supra note 173,
at 31 (1974), thus producing a murder rate 3.7 times the national average.
Yet no one would suggest locking up and treating all black people or
all young people on the basis of those statistics.
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the rankest speculation175-we would have to treat 15,360 schizo-
phrenics in order to save the life of one potential victim per
year.1 7 6 Meanwhile, according to our statistics, from one to two
of those treated would have died from agranulocytosis.
Suicide among schizophrenics: Nor does it appear that
schizophrenics commit suicide at a rate significantly higher than
does the general population. Studies of schizophrenics resident
in public hospitals in New York and California showed annual
suicide rates ranging from 30 to 43 out of 100,000, rates that were
about three or four times the suicide rates in the general popula-
tion. 77 Obviously the hospitalized population of schizophrenics
is not representative of all schizophrenics, and whether the hos-
pital prevents or precipitates suicide is a debatable question,'17
but again these are the best statistics we have. If drug treatment
of schizophrenia would reduce the suicide rate among schizo-
phrenics to that of the general population, we would have to cure
about 5000 patients to save one life a year. There is a fifty-fifty
chance that one of those patients would die from agranulocytosis,
so that the net benefit from treatment is speculative at best.
Moreover, even if we were sure treatment would affect suicide
rates, we would have to ask whether we are willing to incarcerate
175. There is no evidence for this assumption, or against it, for long-
term studies of the effectiveness of drug treatment have a tendency to
exclude subjects with any history of serious homicidal behavior. See,
e.g., The Collaborative Study Group, supra note 112, at 55; cf. Herz, En-
dicott, Sitzer & Mesnikoff, Day Versus Inpatient Hospitalization: A
Controlled Study, 127 AM. J. PSYcmAT. 1371, 1372 (1971) (excluding from
study 6.8 percent of admitted patients for having a "possibility of vio-
lence").
176. The mathematics is simple. If there are 15,360 schizophrenics
untreated and on the loose, in a given year they will commit 2.7 murders;
if we give them treatment which reduces the murderer rate to one per
10,752, that same 15,360 will commit 1.7 murders.
177. See M. KRAMER, E. POLLACK, R. REDICK & B. LOCKE, MENTAL
DIsORDtRs/SuIcIDE 226, table 7.21 (1972).
178. Studies have shown that the suicide rate among hospitalized
mental patients is higher than among the general population, see, e.g.,
Farberow & MacKinnon, A Suicide Prediction Schedule for Neuropsy-
chiatric Hospital Patients, 158 J. NEav. & MENT. Dis. 408 (1974) (suicide
rate in V.A. neuropsychiatric hospitals is 250 out of 100,000; this is 25
times the rate in the general population), and rises even higher immedi-
ately after release. Temoche, Pugh & MacMahon, Suicide Rates Among
Current and Former Mental Institution Patients, 138 J. NERV. & MENT.
Dis. 124 (1964) (suicide rate in hospitals is 1.6 to 2.4 times that of the
general population; suicide rate among former patients within first six
months of release is 34 times that in the general population). For a
vivid description of why a public mental hospital might drive one to
suicide, see K. DONALDSON, INSANITY INSIDE OUT (1976).
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5000 people for at least a matter of weeks in order to save a
single life.
III. CONCLUSION
It appears that although there is a strong likelihood that an
appropriately diagnosed schizophrenic will benefit from treat-
ment with antipsychotic drugs, the precise nature of the benefit
is as yet uncertain, the dangers of treatment are not inconsider-
able, and the dangers that the treatment might avoid are not
great. On the whole, then, if we use cases like Georgetown and
Jacobson to guide us, the conclusion must be that involuntary
treatment of schizophrenics with antipsychotic drugs is not justi-
fied; our hypothetical schizophrenic ought not be committed to
the hospital for treatment.
The implications of this evaluation of the research concern-
ing schizophrenia and the psychotropic drugs go further than the
involuntary treatment of schizophrenics with chlorpromazine.
Since psychiatrists have not proved any form of treatment other
than drugs to be effective in treating mental illness, my analysis
would suggest that, if the burden of proving effectiveness is, as
it should be, placed on the state, no other form of treatment may
be forced on refusing patients. This conclusion is fortified by
the fact that the literature on schizophrenia and the psychotropic
drugs is far more complete than the literature on any form of
treatment for any other mental illness. Thus the case for forced
treatment of other mental illnesses is likely to be even weaker
than the case that I have set out in this Article. And if that
is so, then confinement and treatment of an objecting mental
patient, no matter what his disorder, should be impermissible.
This would seem to leave "dangerousness" the sole reason for
confining the mentally ill, for treatment or otherwise. While I
do not intend to discuss this issue, it is important to be aware
how limited a justification this is. Presently there is no known
method of predicting serious, dangerous behavior with any de-
gree of accuracy; 179 all attempts over-predict dangerousness, so
that confinements based on these predictions will inevitably
result in the confinement of large numbers of persons who never
would have committed any dangerous act.
179. See, e.g., Diamond, The Psychiatric Prediction of Dangerousness,
123 U. PA. L. REV. 439 (1974); Ennis & Litwack, supra note 31, at 711-16;
Greenberg, Involuntary Psychiatric Commitments to Prevent Suicide, 49
N.Y.U.L. REv. 227 (1974); Rubin, Prediction of Dangerousness in Men-
tally Ill Criminals, 27 ARcH. GEN. PSYCHIAT. 397 (1972).
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If we eliminate from "police power" commitments those cases
where the danger is predicted for the distant future, we reduce
"police power" commitments to the traditional power of the po-
lice to arrest, confine, and restrain someone who is presently dan-
gerous to himself or others: for example, someone who is pres-
ently attacking other people or is presently unconscious. Once
the person is calm or conscious, as the case may be, the reason
for confinement (assuming there is no pending criminal charge
arising out of the behavior) ceases, so ought the confinement to
cease. This analysis leaves some questions unanswered: for ex-
ample, are there dangers of greater predictability and smaller
magnitude than physical injury to one's self or others-for exam-
ple, exhibitionism"1 0-which would justify confinement? At
what stage of presently dangerous behavior-threat or assault-
ought the police power be allowed to intervene? I leave these
questions for others to deal with. At present it suffices to say
that neither treatment nor dangerousness provides a justification
for the vast majority of those mentally ill persons whom the state
confines against their will.
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B: Burdock Ward Behavior
Rating Scale
C: Clinical Estimate of
Psychiatric Status








P: Psychotic Reaction Profile
R: Rorschach
S: Shipley-Hartford
W: Weschier Adult Intelli-
gence Scale
Unique Rating Devices
1. Rating scale for 20 psychotic
signs
2. Combined numerical rating
for delusions, hallucinations
and disturbed behavior by
psychiatrist and each of 2
ward nurses.
3. Psychiatric scale of target
symptoms
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